var title_f43_2_44064="Erb palsy";
var content_f43_2_44064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erb palsy after traction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: O'Doherty, N. Atlas of the newborn. JB Lippincott, Philadelphia, 1979. p. 159. Copyright &copy; 1979 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44064=[""].join("\n");
var outline_f43_2_44064=null;
var title_f43_2_44065="McBurney incision 3";
var content_f43_2_44065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    McBurney incision 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (E) External oblique closed with running suture. (F) Delayed closure of skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44065=[""].join("\n");
var outline_f43_2_44065=null;
var title_f43_2_44066="Intermediate case 9 with answer";
var content_f43_2_44066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Wandering atrial pacemaker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 99px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing prominent beat-to-beat variation in P wave axis or morphology indicative of a wandering (shifting) atrial pacemaker. The P wave is upright in the first and third beats, biphasic in the last beat, and flat or inverted in the other beats. This pattern may occur as a physiologic variant, especially during sleep, or as a manifestation of drug toxicity (digitalis, beta-blockers, calcium channel blockers) or the sick sinus syndrome. The relatively slow rate distinguishes this arrhythmia from multifocal atrial tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44066=[""].join("\n");
var outline_f43_2_44066=null;
var title_f43_2_44067="Hemifacial microsomia";
var content_f43_2_44067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemifacial microsomia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left-sided hemifacial microsomia. Bilateral hearing aids for mixed sensorineural and conductive loss.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold DH, MD, and Weingeist TA, MD, PhD. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44067=[""].join("\n");
var outline_f43_2_44067=null;
var title_f43_2_44068="Bedaquiline: Patient drug information";
var content_f43_2_44068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bedaquiline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12869?source=see_link\">",
"     see \"Bedaquiline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15883661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4089942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause a long QT on ECG. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15883663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15883662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4089944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bedaquiline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15883667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4090164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a long QT on ECG, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15883668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15883669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Coughing up blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15883665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15883666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4089946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All weeks:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4089948",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Weeks 1 and 2:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4090143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Week 3 or more:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15883670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15883671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87618 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44068=[""].join("\n");
var outline_f43_2_44068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883661\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883663\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883662\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883667\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883668\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883669\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883665\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883666\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883670\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883671\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12869?source=related_link\">",
"      Bedaquiline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_2_44069="Clinical manifestations of hyperkalemia in adults";
var content_f43_2_44069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of hyperkalemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44069/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44069/contributors\">",
"     David B Mount, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44069/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44069/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44069/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44069/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/2/44069/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is a common clinical problem that is most often due to impaired urinary potassium excretion due to acute or chronic kidney disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disorders or drugs that inhibit the renin-angiotensin-aldosterone axis. Therapy for hyperkalemia due to potassium retention is ultimately aimed at inducing potassium loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In some cases, the primary problem is movement of potassium out of the cells, even though the total body potassium may be reduced. Redistributive hyperkalemia most commonly occurs in uncontrolled hyperglycemia (eg, diabetic ketoacidosis or hyperosmolar hyperglycemic state). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Potassium depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of hyperkalemia will be reviewed here. The causes, diagnosis, treatment, and prevention of hyperkalemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious manifestations of hyperkalemia are muscle weakness or paralysis, cardiac conduction abnormalities, and cardiac arrhythmias. These manifestations usually occur when the serum potassium concentration is",
"    <strong>",
"     &ge;7.0",
"     <span class=\"nowrap\">",
"      meq/L",
"     </span>",
"    </strong>",
"    with chronic hyperkalemia or possibly at lower levels with an acute rise in serum potassium. Patients with skeletal muscle or cardiac manifestations typically have one or more of the characteristic ECG abnormalities associated with hyperkalemia.",
"   </p>",
"   <p>",
"    Other manifestations in hyperkalemic patients may be related to the cause of the hyperkalemia, such as polyuria and polydipsia with uncontrolled diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Severe muscle weakness or paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia can cause ascending muscle weakness that begins with the legs and progresses to the trunk and arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. This can progress to flaccid paralysis, mimicking Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Sphincter tone and cranial nerve function are typically intact, and respiratory muscle weakness is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/7\">",
"     7",
"    </a>",
"    ]. These manifestations resolve with correction of the hyperkalemia.",
"   </p>",
"   <p>",
"    In addition to acquired hyperkalemia, there is a genetic disorder hyperkalemic periodic paralysis that is caused by autosomal dominant mutations in the skeletal muscle cell sodium channel. Patients with this disorder develop myopathic weakness during hyperkalemia induced by increased potassium intake or rest after heavy exercise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiac manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia may be associated with electrocardiographic changes that, if present, may suggest the diagnosis before blood test results. Other manifestations include conduction abnormalities and cardiac arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     ECG changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia may be associated with a variety of changes on the electrocardiogram (ECG). Tall peaked T waves with a shortened QT interval are usually the first findings (",
"    <a class=\"graphic graphic_waveform graphicRef80441 \" href=\"mobipreview.htm?11/50/12068\">",
"     waveform 1",
"    </a>",
"    ). As the hyperkalemia gets more severe, there is progressive lengthening of the PR interval and QRS duration, the P wave may disappear, and ultimately the QRS widens further to a sine wave pattern. Ventricular standstill with a flat line on the ECG ensues with complete absence of electrical activity.",
"   </p>",
"   <p>",
"    The progression and severity of ECG changes do not correlate well with the serum potassium concentration as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 90 patients with hyperkalemia (80 percent with a serum potassium below 7.2",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      the probability of ECG abnormalities increased with increasing serum potassium but the ECG was insensitive for the diagnosis of hyperkalemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, the prevalence of ECG changes suggestive of hyperkalemia was independent of severity (43 and 55 percent in patients with a serum potassium less than 6.8",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and those with higher values, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare patients have a normal ECG despite a serum potassium above 9.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ECG manifestations are more likely with rapid onset hyperkalemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/11\">",
"       11",
"      </a>",
"      ], and the presence of concomitant hypocalcemia, acidemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyponatremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/8,12\">",
"       8,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the unreliable sensitivity, serial measurements of the serum potassium concentration should guide therapy in stable patients with hyperkalemia. The ECG cannot be reliably used to monitor the efficacy of hyperkalemia therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, peaked T waves alone are not specific for hyperkalemia, being seen in the early phase of acute myocardial infarction and with early repolarization, and some patients with left ventricular hypertrophy (",
"    <a class=\"graphic graphic_table graphicRef73040 \" href=\"mobipreview.htm?23/16/23819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperkalemia can also cause a type I Brugada pattern in the ECG, with a pseudo-right bundle branch block and persistent \"coved\" ST segment elevation in at least two precordial leads. This \"hyperkalemic Brugada sign\" occurs in critically ill patients with significant hyperkalemia (serum potassium concentration &gt;7.0",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    and can be differentiated from genetic Brugada syndrome by an absence of P waves, marked QRS widening,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an abnormal QRS axis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Conduction abnormalities and arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia can lead to a variety of conduction abnormalities and arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conduction abnormalities that may be seen include right bundle branch block, left bundle branch block, bifascicular block, and advanced atrioventricular block [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac arrhythmias associated with hyperkalemia include sinus bradycardia, sinus arrest, slow idioventricular rhythms, ventricular tachycardia, ventricular fibrillation, and asystole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reduced urinary acid excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia interferes with renal ammonium (NH4+) excretion, thereby limiting acid excretion and possibly leading to the development of metabolic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. This association has been well described in humans as illustrated by the following observations; similar findings have been described in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two case reports described patients with isolated hyporeninemic hypoaldosteronism and mild to moderate chronic kidney disease who had hyperkalemia, metabolic acidosis, and reduced urinary NH4+ excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/20\">",
"       20",
"      </a>",
"      ]. Correction on the hyperkalemia with a potassium-sodium exchange resin led to resolution of the acidemia and normalization of urinary NH4+ excretion.",
"     </li>",
"     <li>",
"      In a study in normal men, ingesting a high potassium diet for five days was associated with a significant reduction in both ammonium and net acid excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least three mechanisms are thought to contribute to the hyperkalemia-induced diminution in ammonium secretion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intracellular alkalosis as entry of some of the excess potassium into the cells is associated with hydrogen ion movement out the cells to maintain electroneutrality. The intracellular alkalosis will reduce both ammonium excretion and bicarbonate reabsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/20,22-25\">",
"       20,22-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced NH4+ reabsorption in the thick ascending limb of the loop of Henle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/23,26\">",
"       23,26",
"      </a>",
"      ]. In normal subjects, NH4+ can substitute for potassium on the Na-K-2Cl cotransporter in the luminal membrane, a process that is essential for medullary recycling of NH4+, which is subsequently secreted into the medullary collecting duct [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/27\">",
"       27",
"      </a>",
"      ]. With hyperkalemia, potassium competes with NH4+ for transport by the Na-K-2Cl cotransporter, resulting in reductions in medullary recycling and NH4+ secretion and the development of metabolic acidosis.",
"     </li>",
"     <li>",
"      Diminished ammoniagenesis, mediated in part by reduced glutamate deamination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle weakness and cardiac manifestations induced by hyperkalemia are related to impaired neuromuscular transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. The generation of an action potential (called membrane excitability) is related both to the magnitude of the resting membrane potential and to the activation state of membrane sodium channels. Opening of these sodium channels, leading to the passive diffusion of extracellular sodium into the cells, is the primary step in this process.",
"   </p>",
"   <p>",
"    According to the Nernst equation, the resting electrical potential across the cell membrane is related to the ratio of the extracellular to intracellular potassium concentration. An elevation in the extracellular (plasma) potassium concentration decreases this ratio; makes the resting potential less electronegative and partially depolarizing the cell membrane.",
"   </p>",
"   <p>",
"    The less negative resting potential will initially increase membrane excitability, since a lesser depolarizing stimulus is required to generate an action potential. However, the later effect is different. Persistent depolarization inactivates sodium channels in the cell membrane, thereby producing a net decrease in membrane excitability that may be manifested clinically by impaired cardiac conduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuromuscular weakness or paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful monitoring of the ECG and muscle strength are indicated to assess the functional consequences of hyperkalemia. Severe muscle weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marked electrocardiographic changes, including conduction abnormalities and arrhythmias, are potentially life-threatening and require immediate treatment. These manifestations usually occur when the serum potassium concentration is",
"    <strong>",
"     &ge;7.0",
"     <span class=\"nowrap\">",
"      meq/L",
"     </span>",
"    </strong>",
"    with chronic hyperkalemia or possibly at lower levels with an acute rise in serum potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=see_link&amp;anchor=H11#H11\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid increases in serum potassium cause more pronounced cardiac toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/30\">",
"     30",
"    </a>",
"    ]. A careful history should assess the probable cause of the hyperkalemia (eg, tissue breakdown) and the expected rate of change in serum potassium; treatment should be adjusted accordingly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44069/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/34/15906?source=see_link\">",
"       \"Patient information: Hyperkalemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14991202\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most serious manifestations of hyperkalemia are ascending muscle weakness or paralysis, cardiac conduction abnormalities, and cardiac arrhythmias. These usually occur when the serum potassium concentration is &ge;7.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      if hyperkalemia is chronic or lower if hyperkalemia is acute. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG) changes associated with hyperkalemia include tall peaked T waves with a shortened QT interval; progressive lengthening of the PR interval and QRS duration; disappearance of the P wave; and widening of the QRS complex to a sine wave pattern. The progression and severity of ECG changes do not correlate well with the serum potassium concentration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'ECG changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conduction abnormalities associated with hyperkalemia include right bundle branch block, left bundle branch block, bifascicular block, and advanced atrioventricular block. Cardiac arrhythmias associated with hyperkalemia include sinus bradycardia, sinus arrest, slow idioventricular rhythms, ventricular tachycardia, ventricular fibrillation, and asystole. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Conduction abnormalities and arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperkalemia may cause metabolic acidosis by interfering with renal ammonium (NH4+) excretion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Reduced urinary acid excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The functional consequences of hyperkalemia are assessed by careful monitoring of the ECG and muscle strength. Severe muscle weakness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      marked electrocardiographic changes may require immediate treatment. Rapid increases in serum potassium cause more pronounced cardiac toxicity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mount, DB, Zandi-Nejad, K. Disorders of Potassium Balance. In: Brenner and Rector's The Kidney, 8th ed, Brenner BM (Ed), W.B Saunders Co, Philadelphia 2008. p.547.",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, Mc-Graw Hill, New York 2001. p.913.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/3\">",
"      Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant 2003; 18:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/4\">",
"      FINCH CA, SAWYER CG, FLYNN JM. Clinical syndrome of potassium intoxication. Am J Med 1946; 1:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/5\">",
"      Evers S, Engelien A, Karsch V, Hund M. Secondary hyperkalaemic paralysis. J Neurol Neurosurg Psychiatry 1998; 64:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/6\">",
"      BELL H, HAYES WL, VOSBURGH J. HYPERKALEMIC PARALYSIS DUE TO ADRENAL INSUFFICIENCY. Arch Intern Med 1965; 115:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/7\">",
"      Freeman SJ, Fale AD. Muscular paralysis and ventilatory failure caused by hyperkalaemia. Br J Anaesth 1993; 70:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/8\">",
"      Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol 2008; 3:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/9\">",
"      Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998; 158:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/10\">",
"      Szerlip HM, Weiss J, Singer I. Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis 1986; 7:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/11\">",
"      Surawicz B, Chlebus H, Mazzoleni A. Hemodynamic and electrocardiographic effects of hyperpotassemia. Differences in response to slow and rapid increases in concentration of plasma K. Am Heart J 1967; 73:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/12\">",
"      Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant 2002; 17:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/13\">",
"      Somers MP, Brady WJ, Perron AD, Mattu A. The prominent T wave: electrocardiographic differential diagnosis. Am J Emerg Med 2002; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/14\">",
"      Arnsdorf MF. Electrocardiogram in Hyperkalemia: electrocardiographic pattern of anteroseptal myocardial infarction mimicked by hyperkalemia-induced disturbance of impulse conduction. Arch Intern Med 1976; 136:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/15\">",
"      Littmann L, Monroe MH, Taylor L 3rd, Brearley WD Jr. The hyperkalemic Brugada sign. J Electrocardiol 2007; 40:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/16\">",
"      Bashour T, Hsu I, Gorfinkel HJ, et al. Atrioventricular and intraventricular conduction in hyperkalemia. Am J Cardiol 1975; 35:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/17\">",
"      Greenberg A. Hyperkalemia: treatment options. Semin Nephrol 1998; 18:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/18\">",
"      Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000; 18:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/19\">",
"      Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol 2009; 20:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/20\">",
"      Szylman P, Better OS, Chaimowitz C, Rosler A. Role of hyperkalemia in the metabolic acidosis of isolated hypoaldosteronism. N Engl J Med 1976; 294:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/21\">",
"      Matsuda O, Nonoguchi H, Tomita K, et al. Primary role of hyperkalemia in the acidosis of hyporeninemic hypoaldosteronism. Nephron 1988; 49:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/22\">",
"      Tannen RL, Wedell E, Moore R. Renal adaptation to a high potassium intake. The role of hydrogen ion. J Clin Invest 1973; 52:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/23\">",
"      DuBose TD Jr, Good DW. Effects of chronic hyperkalemia on renal production and proximal tubule transport of ammonium in rats. Am J Physiol 1991; 260:F680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/24\">",
"      FULLER GR, MACLEOD MB, PITTS RF. Influence of administration of potassium salts on the renal tubular reabsorption of bicarbonate. Am J Physiol 1955; 182:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/25\">",
"      Jaeger P, Karlmark B, Giebisch G. Ammonium transport in rat cortical tubule: relationship to potassium metabolism. Am J Physiol 1983; 245:F593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/26\">",
"      DuBose TD Jr, Good DW. Chronic hyperkalemia impairs ammonium transport and accumulation in the inner medulla of the rat. J Clin Invest 1992; 90:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/27\">",
"      Good DW. Ammonium transport by the thick ascending limb of Henle's loop. Annu Rev Physiol 1994; 56:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/28\">",
"      Sleeper RS, Belanger P, Lemieux G, Preuss HG. Effects of in vitro potassium on ammoniagenesis in rat and canine kidney tissue. Kidney Int 1982; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     Berne, RM, Levy, MN. Cardiovascular Physiology, 4th Ed, Mosby, St Louis 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/30\">",
"      Paice B, Gray JM, McBride D, et al. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed) 1983; 286:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44069/abstract/31\">",
"      Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 2000; 160:1605.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2342 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44069=[""].join("\n");
var outline_f43_2_44069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14991202\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Severe muscle weakness or paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiac manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - ECG changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Conduction abnormalities and arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reduced urinary acid excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14991202\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2342|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/16/23819\" title=\"table 1\">",
"      Differential diagnosis of tall (peaked) T waves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2342|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?11/50/12068\" title=\"waveform 1\">",
"      EKG peaked T waves in hyperkalemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/34/15906?source=related_link\">",
"      Patient information: Hyperkalemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_2_44070="Treatment and prevention of acute rheumatic fever";
var content_f43_2_44070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of acute rheumatic fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     Allan Gibofsky, MD, JD, FACP, FCLM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     John B Zabriskie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44070/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/2/44070/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever (ARF) is a nonsuppurative complication of pharyngeal infection with group A streptococcus. Signs and symptoms of ARF develop two to three weeks following pharyngitis and include arthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In developing areas of the world, acute rheumatic fever and rheumatic heart disease are estimated to affect nearly 20 million people and are the leading causes of cardiovascular death during the first five decades of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States and other developed countries, the incidence of ARF is much lower, likely due to improved hygienic standards and routine use of antibiotics for acute pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no therapy that slows progression of valvular damage in the setting of ARF. There are three major goals of treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic relief of acute disease manifestations",
"     </li>",
"     <li>",
"      Eradication of the group A beta-hemolytic streptococcus (GAS)",
"     </li>",
"     <li>",
"      Prophylaxis against future GAS infection to prevent recurrent cardiac disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to treatment and secondary prevention of rheumatic fever will be reviewed here. Issues related to primary prevention (eg, treatment of streptococcal tonsillopharyngitis) and the epidemiology, pathogenesis, clinical manifestations and diagnosis of acute rheumatic fever are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute rheumatic fever consists of antibiotic therapy, heart failure management, and anti-inflammatory therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute rheumatic fever should be initiated on antibiotic therapy to eradicate GAS carriage. Treatment should proceed as delineated for management of streptococcal pharyngitis, whether or not pharyngitis is present at the time of diagnosis (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"mobipreview.htm?21/29/21981\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, household contacts should have throat cultures performed; those with positive results should also receive a full course of antibiotic therapy, even if asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Carditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe carditis (significant cardiomegaly, congestive heart failure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    third-degree heart block) should be treated with conventional therapy for heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Valve surgery may be necessary when heart failure due to regurgitant lesions cannot be managed with medical therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Surgical outcomes are generally better if valve surgery can be performed when carditis is quiescent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/6\">",
"     6",
"    </a>",
"    ]. Valve repair, if feasible, is preferred over valve replacement since repair avoids the need for long-term anticoagulation associated with mechanical valves and the long-term risk of deterioration of a bioprosthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    (80 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in children and 4 to 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in adults) is the major anti-inflammatory agent for relief of symptoms due to acute rheumatic fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/8\">",
"     8",
"    </a>",
"    ]. The efficacy of other anti-inflammatory drugs in the setting of active rheumatic carditis is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. A meta-analysis of eight randomized trials including 996 patients with acute rheumatic fever found no significant difference in the risk of cardiac disease at one year between the corticosteroid-treated and aspirin-treated groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/13\">",
"     13",
"    </a>",
"    ]. No reduction in the risk of heart valve lesions was observed with corticosteroids or intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arthritis and rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-inflammatory agents are the mainstay of symptomatic management due to acute rheumatic fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    (80 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in children and 4 to 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in adults) is helpful for reducing discomfort related to arthritis and fever. Anti-inflammatory therapy should be continued until all symptoms have resolved. Normalization of inflammatory markers (erythrocyte sedimentation rate and C-reactive protein concentration) may be used as indicator of resolution. The rash associated with ARF is temporary and does not require specific treatment, although antihistamines may help to alleviate pruritus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/47/2807?source=see_link\">",
"     \"Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of initial and recurrent attacks of rheumatic fever depends on control of group A streptococcal tonsillopharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of initial attack of rheumatic fever (primary prevention) is accomplished by prompt diagnosis and antibiotic treatment of group A streptococcal tonsillopharyngitis. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate antibiotic treatment of streptococcal pharyngitis prevents acute rheumatic fever in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/16\">",
"     16",
"    </a>",
"    ]. However, at least one third of acute rheumatic fever episodes occur in the setting of inapparent streptococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, rheumatic fever is not preventable in symptomatic patients who do not seek medical care.",
"   </p>",
"   <p>",
"    Streptococcal skin infections (such as impetigo or pyoderma) have not been proven to lead to acute rheumatic fever. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=see_link\">",
"     \"Impetigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had an attack of rheumatic fever and develop subsequent GAS pharyngitis are at high risk for a recurrent attack of rheumatic fever, with progression in severity of rheumatic heart disease from the initial episode. The most effective method to limit progression of rheumatic heart disease severity is prevention of recurrent GAS pharyngitis, especially since GAS infection need not be symptomatic to trigger a recurrent attack of rheumatic fever.",
"   </p>",
"   <p>",
"    For these reasons, prevention of recurrent rheumatic fever (secondary prevention) requires continuous antimicrobial prophylaxis, rather than recognition and treatment of acute GAS pharyngitis episodes. Continuous prophylaxis is warranted for patients with well-documented history of rheumatic fever (including cases with Syndenham chorea as the sole manifestation) and those with definite evidence of rheumatic heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to initiation of prophylaxis, a full therapeutic course of antibiotic therapy should be given to patients with acute rheumatic fever to eradicate residual GAS, even if a throat culture is negative (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"mobipreview.htm?21/29/21981\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Primary prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prophylactic antibiotics should be initiated immediately at the end of the therapeutic antibiotic course. During the course of prophylaxis, patients and their household contacts who develop acute episodes of group A streptococcal pharyngitis should be evaluated and treated promptly as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prevention for prevention of recurrent rheumatic fever consists of years of prophylactic antibiotic administration. The total duration depends on risk of recurrent rheumatic fever and severity of disease.",
"   </p>",
"   <p>",
"    The risk of recurrent rheumatic fever depends on several factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The number of previous attacks",
"     </li>",
"     <li>",
"      Time since the last attack",
"     </li>",
"     <li>",
"      Risk of exposure to streptococcal infections",
"     </li>",
"     <li>",
"      Patient age",
"     </li>",
"     <li>",
"      Presence or absence of cardiac involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk is increased among individuals with ongoing exposure to streptococcal infections including children, those in close contact with children (parents, healthcare workers) and those living in crowded situations (college students, military personnel) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/18\">",
"     18",
"    </a>",
"    ]. Risk increases with number of previous attacks but decreases as the interval lengthens since the most recent attack.",
"   </p>",
"   <p>",
"    The optimal duration of antibiotic prophylaxis following acute rheumatic fever is uncertain. Patients who have had rheumatic carditis (with or without valvular disease) are at relatively high risk for recurrent carditis and are likely to sustain increasingly severe cardiac involvement with each recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Therefore, in general, prophylaxis in the setting of carditis should continue until the patient is a young adult (21 years of age), which is usually 10 years from an acute attack with no recurrence (",
"    <a class=\"graphic graphic_table graphicRef55223 \" href=\"mobipreview.htm?26/9/26779\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/4,21,22\">",
"     4,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach was evaluated in a Chilean study of 59 patients with history of ARF judged to be at relatively low risk for recurrence of acute rheumatic fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/22\">",
"     22",
"    </a>",
"    ]. Among patients with history of ARF without carditis, prophylaxis was discontinued after 5 years or at age 18 (whichever was longer). During 3349 patient-months of followup, only two acute rheumatic fever recurrences were observed (0.7 per 100 patient-years). These data suggest that acute rheumatic fever prophylaxis can likely be discontinued safely in young adults judged to be at low risk for recurrence who are maintained under careful prospective surveillance.",
"   </p>",
"   <p>",
"    The duration of prophylaxis following acute rheumatic fever is outlined by severity category in the table (",
"    <a class=\"graphic graphic_table graphicRef55223 \" href=\"mobipreview.htm?26/9/26779\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. Antibiotic prophylaxis should continue even after valve surgery, including prosthetic valve replacement.",
"   </p>",
"   <p>",
"    Upon reaching the end of a planned course for secondary prophylaxis, the risk for GAS exposure and severity of valvular disease should be reviewed. A decision regarding cessation or continuation of antibiotic prophylaxis should be made based on individual clinical risks and benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred antibiotic approach for secondary prevention of recurrent rheumatic fever is administration of long acting benzathine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (Bicillin L-A) intramuscularly every four weeks (",
"    <a class=\"graphic graphic_table graphicRef68830 \" href=\"mobipreview.htm?11/32/11788\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. Since the early descriptions of benzathine penicillin use in the 1940s and 1950s, there are data suggesting that some benzathine penicillin preparations may have a shorter duration of protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/25\">",
"     25",
"    </a>",
"    ]; further study is needed. A shorter dosing interval (eg, administration every two to three weeks) is appropriate for populations in which the incidence of rheumatic fever is particularly high. This approach is also warranted for individuals in low-incidence regions who have had recurrent acute rheumatic fever despite adherence to a regimen administered every four weeks.",
"   </p>",
"   <p>",
"    The long-term benefits of intramuscular benzathine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    prophylaxis outweigh the risk of allergic reaction, as life-threatening allergic reactions are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the advantages of this approach must be weighed against the inconvenience and pain associated with injection.",
"   </p>",
"   <p>",
"    Options for oral prophylaxis include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    and macrolides. Success with oral prophylaxis depends on patient adherence, so clear communication regarding the importance of prophylaxis and how antibiotics should be taken is critical. Even with optimal adherence, the risk of recurrence is higher in individuals receiving oral prophylaxis than those receiving intramuscular benzathine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/27\">",
"     27",
"    </a>",
"    ]. This was illustrated in a controlled trial of 405 children and adolescents with rheumatic fever assigned to receive four weeks of intramuscular benzathine penicillin G, oral potassium penicillin G or oral sulfadiazine. In the first two years of the study, streptococcal infections recurred in 7, 20 and 24 percent of patients, respectively; rheumatic fever recurred in 0, 4.8, and 2.7 percent of the patients, respectively.",
"   </p>",
"   <p>",
"    Therefore, parenteral prophylaxis is preferred for patients at high risk for rheumatic fever recurrence; oral agents are appropriate for patients at lower risk for rheumatic fever recurrence. Accordingly, switching from intramuscular to oral prophylaxis once patients have reached young adulthood and have remained free of rheumatic attacks is appropriate.",
"   </p>",
"   <p>",
"    The preferred oral agent is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef68830 \" href=\"mobipreview.htm?11/32/11788\">",
"     table 3",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     Sulfadiazine",
"    </a>",
"    or sulfisoxazole is appropriate for patients allergic to penicillin; this antibiotic class is effective for preventing GAS infection although it cannot be used to achieve eradication. An oral macrolide such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is acceptable for patients allergic to both penicillin and sulfa drugs.",
"   </p>",
"   <p>",
"    Prior to initiation of prophylaxis, a full therapeutic course of antibiotic therapy should be given to patients with acute rheumatic fever to eradicate residual GAS, even if a throat culture is negative (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"mobipreview.htm?21/29/21981\">",
"     table 1",
"    </a>",
"    ). Prophylactic antibiotics should be initiated immediately at the end of the therapeutic antibiotic course.",
"   </p>",
"   <p>",
"    During the course of prophylaxis, patients and their household contacts who develop acute episodes of group A streptococcal pharyngitis should be evaluated and treated promptly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Poststreptococcal reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poststreptococcal reactive arthritis (PSRA) is a reactive arthritis that occurs after a symptom-free interval following GAS pharyngitis. It differs from the arthritis associated with ARF, as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PSRA can be difficult to distinguish from arthritis associated with ARF on clinical grounds, and a small proportion of patients with PSRA have been observed to develop valvular heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For this reason, some favor administering secondary prophylaxis in the setting of suspected PSRA for up to one year after the onset of symptoms, although the efficacy of this approach is not well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44070/abstract/4\">",
"     4",
"    </a>",
"    ]. Evidence of valvular disease after one year should prompt continued prophylaxis as outlined in the preceding sections, and it may be presumed that the presenting symptoms were manifestations of acute rheumatic fever. In the absence of valvular disease after one year, antibiotic prophylaxis may be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with acute rheumatic fever be initiated on antibiotic therapy as delineated for eradication of streptococcal pharyngitis, whether or not pharyngitis is present at the time of diagnosis (",
"      <a class=\"graphic graphic_table graphicRef64596 \" href=\"mobipreview.htm?21/29/21981\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe carditis should be treated with conventional therapy for heart failure. Valve surgery may be necessary when heart failure due to regurgitant lesions cannot be managed with medical therapy alone.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is the mainstay of symptomatic management due to acute rheumatic fever. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Carditis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Arthritis and rash'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of initial attack of rheumatic fever (primary prevention) is accomplished by prompt diagnosis and antibiotic treatment of group A streptococcal tonsillopharyngitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"       \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention of recurrent rheumatic fever (secondary prevention) requires prevention of recurrent GAS pharyngitis. We recommend continuous antimicrobial prophylaxis, rather than recognition and treatment of acute GAS pharyngitis episodes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Secondary prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, prophylaxis in the setting of carditis should continue until the patient is a young adult (18 years of age), which is usually 10 years from an acute attack with no recurrence (",
"      <a class=\"graphic graphic_table graphicRef55223 \" href=\"mobipreview.htm?26/9/26779\">",
"       table 2",
"      </a>",
"      ). At the end of a planned course for secondary prophylaxis, the risk for GAS exposure and severity of valvular disease should be reviewed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest long-acting benzathine",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      for secondary prevention of recurrent rheumatic fever (",
"      <a class=\"graphic graphic_table graphicRef68830 \" href=\"mobipreview.htm?11/32/11788\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Switching from intramuscular to oral prophylaxis once patients have reached young adulthood and have remained free of rheumatic attacks is appropriate. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antibiotic selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest administering secondary prophylaxis in the setting of suspected poststreptococcal reactive arthritis for up to one year after the onset of symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Evidence of valvular disease after one year should prompt continued prophylaxis; otherwise, antibiotic prophylaxis may be discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/1\">",
"      RAMMELKAMP CH Jr, STOLZER BL. The latent period before the onset of acute rheumatic fever. Yale J Biol Med 1961; 34:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/2\">",
"      Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/3\">",
"      Miyake CY, Gauvreau K, Tani LY, et al. Characteristics of children discharged from hospitals in the United States in 2000 with the diagnosis of acute rheumatic fever. Pediatrics 2007; 120:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/4\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/5\">",
"      Cilliers AM. Rheumatic fever and its management. BMJ 2006; 333:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/6\">",
"      Skoularigis J, Sinovich V, Joubert G, Sareli P. Evaluation of the long-term results of mitral valve repair in 254 young patients with rheumatic mitral regurgitation. Circulation 1994; 90:II167.",
"     </a>",
"    </li>",
"    <li>",
"     National Heart Foundation of Australia (RF/RHD guideline development working group) and the Cardiac Society of Australia and New Zealand. Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia -- an evidence based review. 2006. Available at: www.heartfoundation.com.au/downloads/ARF_RHD_PP-590_Diag-Mgnt_Evidence-Review_0606.pdf (Accessed on December 07, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/8\">",
"      United Kingdom and United States Joint Report: The treatment of acute rheumatic fever in children. Cooperative clinical trial of ACTH, cortisone and aspirin. Circulation 1955; 11:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/9\">",
"      Albert DA, Harel L, Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore) 1995; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/10\">",
"      The natural history of rheumatic fever and rheumatic heart disease. Ten-year report of a cooperative clinical trial of ACTH, cortisone, and aspirin. Circulation 1965; 32:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/11\">",
"      Haffejee IE, Moosa A. A double-blind placebo-controlled trial of prednisone in active rheumatic carditis. Ann Trop Paediatr 1990; 10:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/12\">",
"      Human DG, Hill ID, Fraser CB. Treatment choice in acute rheumatic carditis. Arch Dis Child 1984; 59:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/13\">",
"      Cilliers A, Manyemba J, Adler AJ, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2012; 6:CD003176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/14\">",
"      Stollerman GH. Rheumatic fever. Lancet 1997; 349:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/15\">",
"      STOLLERMAN GH. The use of antibiotics for the prevention of rheumatic fever. Am J Med 1954; 17:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/16\">",
"      DENNY FW, WANNAMAKER LW, BRINK WR, et al. Prevention of rheumatic fever; treatment of the preceding streptococcic infection. J Am Med Assoc 1950; 143:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/17\">",
"      Dajani AS. Current status of nonsuppurative complications of group A streptococci. Pediatr Infect Dis J 1991; 10:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/18\">",
"      BLAND EF, DUCKETT JONES T. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation 1951; 4:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/19\">",
"      Majeed HA, Yousof AM, Khuffash FA, et al. The natural history of acute rheumatic fever in Kuwait: a prospective six year follow-up report. J Chronic Dis 1986; 39:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/20\">",
"      Gordis L, Lilienfeld A, Rodriguez R. Studies in the epidemiology and preventability of rheumatic fever. II. Socio-economic factors and the incidence of acute attacks. J Chronic Dis 1969; 21:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/21\">",
"      Rammelkamp CH Jr. Epidemiology of streptococcal infections. Harvey Lect 1955- 1956; 51:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/22\">",
"      Berrios X, del Campo E, Guzman B, Bisno AL. Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study. Ann Intern Med 1993; 118:401.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation. Geneva. WHO, 20 Oct to 1 Nov, 2001. WHO Tech Rep Ser 2001; 923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/24\">",
"      STOLLERMAN GH, RUSOFF JH. Prophylaxis against group A streptococcal infections in rheumatic fever patients; use of new repository penicillin preparation. J Am Med Assoc 1952; 150:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/25\">",
"      Broderick MP, Hansen CJ, Faix DJ. Factors associated with loss of penicillin G concentrations in serum after intramuscular benzathine penicillin G injection: a meta-analysis. Pediatr Infect Dis J 2012; 31:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/26\">",
"      Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. International Rheumatic Fever Study Group. Lancet 1991; 337:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/27\">",
"      FEINSTEIN AR, WOOD HF, EPSTEIN JA, et al. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. II. Results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N Engl J Med 1959; 260:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/28\">",
"      CREA MA, MORTIMER EA Jr. The nature of scarlatinal arthritis. Pediatrics 1959; 23:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44070/abstract/29\">",
"      Ahmed S, Ayoub EM, Scornik JC, et al. Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles. Arthritis Rheum 1998; 41:1096.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3175 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44070=[""].join("\n");
var outline_f43_2_44070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Carditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arthritis and rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Poststreptococcal reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3175\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3175|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/29/21981\" title=\"table 1\">",
"      Treatment streptococcal pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/9/26779\" title=\"table 2\">",
"      Secondary prophylaxis for rheumatic fever - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/32/11788\" title=\"table 3\">",
"      Secondary prophylaxis for rheumatic fever - Selection of therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/47/2807?source=related_link\">",
"      Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_2_44071="Evaluation and management of lower genital tract trauma in women";
var content_f43_2_44071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of lower genital tract trauma in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44071/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44071/contributors\">",
"     Gretchen Makai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44071/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44071/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44071/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44071/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/2/44071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any female child, adolescent, or adult with a complaint of vaginal pain or genital bleeding or swelling should undergo a careful examination to look for vulvar or vaginal trauma or laceration. It should also be kept in mind that patients with vulvar or vaginal trauma sometimes present with abdominal or low back pain as their chief complaint. External lesions can be identified easily, but need to be carefully evaluated for deeper extension. Internal lesions are more difficult to assess.",
"   </p>",
"   <p>",
"    Patients may not be forthcoming with details of the events that caused the trauma, therefore identifying those at risk is a crucial step in management. The history should always be consistent with the physical findings; further questioning is important if there is a discrepancy. The possibility of sexual abuse or assault must always be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obstetrical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacerations of the cervix, vagina,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vulva commonly occur during childbirth. Risk factors associated with lower genital tract trauma in the obstetrical setting include nulliparity, large baby, precipitous birth, operative delivery,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    episiotomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gynecological",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vulvar trauma &mdash; The rich vascular supply to the perineum places it at risk for bleeding from trauma. Vulvar hematomas are the most common sequelae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adult women, the labia majora are comprised of large fat pads, which act to protect the vulva against injury. In contrast, children lack well-developed fat pads in this area and often engage in play activities predisposing them to vulvar trauma; thus, they are more likely to sustain vulvar injuries than adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35669?source=see_link\">",
"     \"Straddle injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vulvar and perineal injuries in gynecological practice most commonly occur due to blunt trauma, particularly in the straddle position. Bicycle, automobile, or other athletic accidents are often causative events, but coitus-related activity also plays a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal trauma &mdash; Most vaginal injuries occur as a result of penetrating trauma. Causes include nonconsensual or forceful consensual coitus, penetration by a foreign object, pelvic fracture, and hydraulic or pneumatic forces (eg, water or air insufflation from jet ski accidents or water skiing) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. Risk factors include first coitus (usually associated with hymenal lacerations); hypoestrogenic states (menopause, lactation, postpartum); inebriation; history of pelvic irradiation; and anatomic abnormalities (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=see_link\">",
"       \"Diagnosis and management of congenital anomalies of the vagina\"",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple studies have looked for types or patterns of injuries more common in victims of sexual abuse in order to establish etiology of injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. A definitive pattern confirming or refuting abusive versus accidental vulvovaginal trauma has not been determined, despite use of multiple examination tools (vaginoscopy, colposcopy, toluidine blue dye) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pediatric and adolescent age groups, patient history has been shown to be as important as physical examination in determining the cause of trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. In children, hymenal disruption (especially from 3 to 9 o'clock) can be indicative of penetrating injury and should raise suspicion for abuse. It is important to remember that a normal genital exam does not exclude the possibility of sexual abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=see_link&amp;anchor=H3#H3\">",
"     \"Gynecologic examination of the newborn and child\", section on 'History and physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should always be performed in the presence of a chaperone. If sexual abuse, nonconsensual coitus, or excessive brutality is suspected, it is important to take special care to avoid any additional trauma to the victim and to consult a practitioner trained in assessing victims of sexual violence. In addition, it may be necessary to perform specific documentation and procedures to obtain forensic evidence; details are outlined elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain during the examination may be controlled, if necessary, with analgesics or anesthetics, as described below (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Sedation/anesthesia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vulva",
"    </span>",
"    &nbsp;&mdash;&nbsp;The labia, clitoris, urethra, perineum, and rectum are examined at the start of any pelvic examination. It is essential that the examining physician be familiar with normal variants of the external female genitalia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=see_link&amp;anchor=H10#H10\">",
"     \"Gynecologic examination of the newborn and child\", section on 'Evaluation of the hymen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clues to external trauma include skin lacerations, redness, edema, ecchymosis, asymmetry of the labia, and localized tenderness. Labial fluctuance, swelling, and pain can indicate hematoma formation. If gross swelling without ecchymoses is noted, translabial ultrasound can be helpful in distinguishing between edema and a collection of blood. In the area of the Bartholin glands, diagnosis of an acute cyst or abscess should be made with caution in women with a recent history of trauma because hematomas in this region can have a similar presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22375?source=see_link\">",
"     \"Disorders of Bartholin gland\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Perineum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perineum is the supportive layer of tissue between the introitus and the rectum. This area may sustain a significant portion of the force exerted during penetrating trauma. Perineal lacerations or tears are classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First degree - Involving only the perineal skin",
"     </li>",
"     <li>",
"      Second degree - Involving the perineal body and deeper tissues",
"     </li>",
"     <li>",
"      Third degree - Extending into the capsule and muscle of the rectal sphincter",
"     </li>",
"     <li>",
"      Fourth degree - Extending through the sphincter and into the rectal mucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These classifications help the clinician determine both extent of injury and approach to repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection of the vaginal introitus and the hymenal ring can be achieved by gentle downward and outward traction on the",
"    <span class=\"nowrap\">",
"     perineum/inferior",
"    </span>",
"    labia. Internal vaginal examination with a sterile speculum should include rotation of the speculum to entirely visualize all four vaginal walls. The integrity of the vaginal fornices (cervicovaginal junction) must be carefully assessed, as the most commonly reported sites for coital vaginal laceration are the posterior fornix and lateral vaginal walls. A thorough evaluation is important because if the injury is not appropriately diagnosed and managed, inadequate healing may result in a fistula between bladder and vagina or bowel and vagina.",
"   </p>",
"   <p>",
"    In cases of minor lacerations, the pressure of the open speculum may lead to hemostasis temporarily and thus conceal the injury; the lesion may bleed again when pressure is released. Visualizing the laceration while releasing and slowly retracting the speculum will help to prevent this from occurring.",
"   </p>",
"   <p>",
"    If brisk bleeding from any area obscures an adequate examination, the vagina should be packed with sterile gauze and the patient taken to the operating room for evaluation and control. Vaginal trauma may cause serious damage to internal organs, especially the lower urinary tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Urethral catheterization can be useful to look for hematuria, suggestive of bladder injury. However, the urethra itself may be disrupted, in which case catheter placement may be traumatic or very difficult. Cystoscopy, voiding cystourethrogram, or other urologic studies may help elucidate the nature of injury. Urethral injuries should be evaluated by an experienced urologist or urogynecologist prior to intervention.",
"   </p>",
"   <p>",
"    Digital rectal examination is performed to determine sphincter tone, assess mucosal integrity, expose any rectal bleeding, and further evaluate for posterior vaginal injuries. Bony prominences in the pelvis and perineum should be palpated and evaluated for tenderness suggestive of fracture.",
"   </p>",
"   <p>",
"    An upright abdominal film looking for free air under the diaphragm is indicated if there is suspicion that a vaginal laceration has extended into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, penetrating trauma may result in damage to internal organs even in the absence of vaginal mucosal laceration. In most of these case reports, patients were evaluated for hemoperitoneum or small bowel injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/21\">",
"     21",
"    </a>",
"    ]. Fatal air embolism has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/22\">",
"     22",
"    </a>",
"    ]. Such instances highlight the need for thorough patient evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications should be identified, if possible, prior to any intervention. Obtaining intravenous access and choosing an appropriate operative setting are important considerations for all of the procedures described below. Consultation with an experienced emergency department physician, gynecologist, or surgeon and adequate",
"    <span class=\"nowrap\">",
"     sedation/anesthesia",
"    </span>",
"    are of paramount importance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics are not usually required for repairs of vulvar and vaginal trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/23\">",
"     23",
"    </a>",
"    ]. Prophylaxis against sexually transmitted infections is appropriate in individual cases, such as sexual assault victims (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Sexually transmitted infections'",
"    </a>",
"    ) Generally, endocarditis prophylaxis is not indicated for minor vaginal procedures; special circumstances include bladder or bowel involvement and extensive injury, in which cases antimicrobial prophylaxis is recommended.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sedation/anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar and perineal trauma may be associated with pain and discomfort out of proportion to the size of the injury due to the sensitivity of this area.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    (1 percent solution) injected locally is useful for providing anesthesia for suturing and is the most frequently used anesthetic for minor injuries. A small gauge needle (eg, 22) is used for injection; however, a spinal length needle may be needed for reaching deep vaginal areas. The periclitoral region and the perineal skin anterior to the rectum are exquisitely sensitive and special care should be taken to apply adequate analgesia in these areas.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    jelly (2 percent) may be injected into the urethra for pain control during catheterization, but is generally not as effective on the external genitalia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/24\">",
"     24",
"    </a>",
"    ]. Oral or intravenous pain medication may be required for patients in significant distress, and young girls may require conscious sedation. All general anesthesia is given in an anesthetizing setting (operating room). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REPAIR OF LACERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vulva",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar trauma can cause significant bleeding because the area is highly vascular and the loose subcutaneous tissues afford little resistance to hematoma formation (",
"    <a class=\"graphic graphic_picture graphicRef79981 \" href=\"mobipreview.htm?20/12/20676\">",
"     picture 1",
"    </a>",
"    ). Bleeding vessels should be targeted for suture repair, if they can be identified, to prevent collection of blood. Hemostatic superficial lacerations may be left open, but actively bleeding lacerations should be closed. Puncture wounds are cleaned and assessed for deeper trauma and foreign bodies before closing.",
"   </p>",
"   <p>",
"    Before suturing near the clitoris and urethra, the clinician should weigh whether repair of these areas may be more traumatic or painful than leaving the laceration to heal by secondary intention. If repair is needed to achieve hemostasis or tissue reapproximation, a fine absorbable synthetic suture (such as monocryl) is utilized; use of catgut suture may increase post-repair pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/25\">",
"     25",
"    </a>",
"    ], placing shallow through-and-through interrupted sutures to reapproximate skin edges. Deeper lacerations (&gt;3 to 4 mm deep) may require an initial deep suture layer if there is bleeding, but it is important to avoid putting extra foreign material in the wound. If deep lacerations appear infected, then the wound should be packed with saline-moistened gauze two or three-times daily and allowing it to heal by secondary intention.",
"   </p>",
"   <p>",
"    Repair of traumatic vulvovaginal lacerations is the same irrespective of the cause of the injury (obstetrical delivery or nonobstetrical cause) (",
"    <a class=\"graphic graphic_figure graphicRef80076 \" href=\"mobipreview.htm?16/55/17268\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78780 \" href=\"mobipreview.htm?27/24/28036\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62068 \" href=\"mobipreview.htm?41/39/42613\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vagina",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Superficial lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor vaginal trauma is not generally associated with significant pain or blood loss unless a major blood vessel is torn. Bleeding from hymenal injuries is usually minimal and requires no treatment. Superficial vaginal lacerations limited to mucosal and submucosal tissues can be left alone if hemostatic, otherwise styptic (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/18/19747?source=see_link\">",
"     ferric subsulfate",
"    </a>",
"    [Monsel's solution]) or simple tamponade may suffice if bleeding is light. Such lacerations are repaired with fine absorbable synthetic sutures under local anesthesia only if there is a need for hemostasis or tissue reapproximation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/26\">",
"     26",
"    </a>",
"    ]; use of catgut suture may increase post-repair pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/25\">",
"     25",
"    </a>",
"    ]. If electrocautery is used, it is important to avoid deep or widespread thermal injury because of the vagina's proximity to the bowel and bladder, as well as risk of infection in the resulting necrotic tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Deep lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of deep or complicated vaginal lacerations requires both an operator and a surgical assistant, and is best performed in a surgical suite to obtain adequate exposure. Regional or general anesthesia may be needed due to pain and pressure from retraction or extensive suturing. Blood products should be available for transfusion in the event of brisk bleeding.",
"   </p>",
"   <p>",
"    Deep or large vaginal lacerations may be repaired in one or more layers depending upon the tissues involved. A running locked absorbable suture is used to obtain initial hemostasis. The anchoring stitch should be placed above the apex of the laceration, and each stitch should reach the base of the tear to avoid creating pockets for",
"    <span class=\"nowrap\">",
"     hematoma/seroma",
"    </span>",
"    formation. The proximity of the bladder anteriorly, small bowel and rectum posteriorly, and the ureters and uterine vessels deep in the lateral vaginal fornices are important to consider as they can be included in placement of large deep sutures.",
"   </p>",
"   <p>",
"    The mucosal edges are reapproximated with fine absorbable synthetic sutures. If the hymenal ring is involved, it should be reapproximated to itself. The perineum and or rectal sphincter may need additional stitches for support. Repair of third and fourth degree perineal lacerations is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34263?source=see_link\">",
"     \"Delayed surgical management of the disrupted anal sphincter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Emergent use of fibrin sealants has been reported for treatment of vaginal lacerations after surgical management has failed to control bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/27\">",
"     27",
"    </a>",
"    ]. Further information is needed regarding use of these adjuncts for this type of injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep lacerations that appear infected, if hemostatic, may be left open or closed with placement of a drain (",
"    <a class=\"graphic graphic_picture graphicRef80199 graphicRef58229 \" href=\"mobipreview.htm?18/25/18839\">",
"     picture 2A-B",
"    </a>",
"    ). Povidone iodine-moistened vaginal packing is often placed in the vagina for 24 hours after repair to assist in achieving hemostasis. A Foley catheter should be inserted to drain the bladder as a vaginal pack may obstruct outflow from the urethra.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Extension beyond the vagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy or an exploratory laparotomy may be needed for assessment of a deep vaginal laceration that extend through the posterior cul de sac (pouch of Douglas) and into the peritoneal cavity to rule out damage to internal organs. A urologist or urogynecologist should evaluate any trauma extending to the urethra or bladder.",
"   </p>",
"   <p>",
"    Lacerations extending into the rectum should be evaluated and treated by an experienced gynecologic or general surgeon. In severe cases, diverting colostomy may be indicated. These lacerations have a high incidence of infection, wound breakdown, and risk of rectovaginal fistula formation and sphincter incontinence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF HEMATOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of vulvar and vaginal hematomas varies; the literature is inconclusive regarding benefits of conservative treatment versus surgical interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Vulva",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, vulvar hematomas are best left undisturbed so as to avoid introducing bacteria and undertaking a potentially difficult surgical procedure (",
"    <a class=\"graphic graphic_picture graphicRef79981 \" href=\"mobipreview.htm?20/12/20676\">",
"     picture 1",
"    </a>",
"    ). Bleeding leading to a vulvar hematoma is often venous and from multiple sites, thus it can be difficult to isolate and control surgically.",
"   </p>",
"   <p>",
"    The rationale for conservative management is that soft tissue swelling and space limitations will cause tamponade of bleeding vessels. Patients may be uncomfortable with such swelling, but they should be reassured the body will naturally reabsorb the blood and edema over time. Ice packs may be applied to the perineum for the first 24 hours to minimize swelling and narcotic or nonnarcotic analgesia are administered to manage pain. Large vulvar hematomas often interfere with urination. A Foley catheter should be placed upon initial evaluation because, if the hematoma is still expanding, late placement may not be possible without sedation or anesthesia (",
"    <a class=\"graphic graphic_picture graphicRef56586 \" href=\"mobipreview.htm?25/57/26514\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/13\">",
"     13",
"    </a>",
"    ]. Some hematomas may rupture spontaneously (",
"    <a class=\"graphic graphic_picture graphicRef50040 \" href=\"mobipreview.htm?0/39/629\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Surgical intervention may be necessary if there is vast expansion of the hematoma on physical examination or a falling hematocrit. Persistent hemorrhage can lead to hemodynamic instability or put the tissue at risk of necrosis. The clinician should be vigilant otherwise bleeding that tracks posteriorly, vaginally, or into the retroperitoneum may not be recognized promptly.",
"   </p>",
"   <p>",
"    If the hematoma is drained, one approach is to make an incision large enough to allow visualization of bleeding vessels, which are ligated if possible. A",
"    <span class=\"nowrap\">",
"     suction/irrigation",
"    </span>",
"    devise may be helpful in clearing the clot and debris (",
"    <a class=\"graphic graphic_picture graphicRef56836 \" href=\"mobipreview.htm?20/20/20806\">",
"     picture 5",
"    </a>",
"    ). The space created by the incision is reapproximated using in interrupted or figure-of-eight stitches of monofilament absorbable suture to avoid trapping bacteria. The incision can then be repaired as described above (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Repair of lacerations'",
"    </a>",
"    above). A drain may be helpful (",
"    <a class=\"graphic graphic_picture graphicRef70417 \" href=\"mobipreview.htm?32/8/32899\">",
"     picture 6",
"    </a>",
"    ), as incision of the hematoma exposes the underlying tissues to a nonsterile environment and predisposes it to infection.",
"   </p>",
"   <p>",
"    An alternate approach is drainage of the hematoma with a small incision with no attempt to visualize and ligate bleeding vessels. We have found this approach to be successful as long as a drain is left in place; we have utilized a word catheter which permits for drainage and decreases the risk of superinfection in a closed space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Interventional vascular procedures for embolization of vessels have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], but are rarely employed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30408?source=see_link\">",
"     \"Interventional radiology in management of gynecological disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of other matrix or tissue hemostatic agents has been reported and may be an alternative option for treatment in difficult cases. The use of a fibrin sealant with hemostatic and tissue-sealing adjunctive properties was successful in a case of refractory bleeding and failed surgical management of an expanding vulvar hematoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to vaginal hematomas is similar to that for vulvar hematomas. Vaginal hematomas larger than approximately 4 cm may need to be opened and evacuated to ligate bleeding vessels. If all bleeding vessels are not ligated adequately before the mucosal edges are closed, another hematoma may develop. If stable, these hematomas can be watched, but if they are enlarging or if bleeding continues, they too should be opened, evacuated, and the bleeding points ligated. Vaginal packing with a povidone iodine-moistened gauze may be helpful for tamponade.",
"   </p>",
"   <p>",
"    As discussed above, the possibility of retroperitoneal bleeding from torn and retracted vessels must also be considered if the patient becomes unstable (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Extension beyond the vagina'",
"    </a>",
"    above). Interventional vascular procedures for embolization of vessels are rarely indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30408?source=see_link\">",
"     \"Interventional radiology in management of gynecological disorders\"",
"    </a>",
"    .) If surgical management fails to control bleeding of an opened vaginal hematoma, emergent use of fibrin sealants may be an option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FOLLOW UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sitz baths are often prescribed two or three times daily to help with hygiene until external lacerations are healing well. Depending upon the extent of trauma, pelvic rest for three to four weeks is also recommended to avoid disruption of healing tissue. Analgesics, such as nonsteroidal antiinflammatory drugs and narcotics, are used for short-term pain control. Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    has minimal efficacy. Further supportive measures include use of vaginal lubricants for coitus and (vaginal) estrogen supplementation in hypoestrogenic females. Pressure necrosis of the swollen external genitalia may be prevented by having the patient rest primarily on her side or back.",
"   </p>",
"   <p>",
"    Patient counseling after vaginal laceration is tailored to individual circumstances, and emotional consequences of such an injuries should not be overlooked. Studies suggest women who suffer trauma of the genital tract are more likely to suffer dyspareunia, sexual dysfunction, and chronic pain of the lower genital tract and pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44071/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with lower genital tract injury in nonobstetrical settings may not be forthcoming with details of the preceding events. The possibility of sexual abuse or assault must always be considered. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vulvar hematomas are the most common sequelae of blunt trauma to the genitalia, whereas most vaginal injuries occur as a result of penetrating trauma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal trauma may cause serious damage to internal organs and injuries to the lower urinary tract. Urethral injuries should be evaluated by an experienced urologist or urogynecologist prior to intervention. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regarding repair of lacerations, before suturing near the clitoris and urethra, the clinician should weigh whether repair of these areas may be more traumatic or painful than secondary healing alone. If repair is needed to achieve hemostasis or tissue reapproximation, then we use fine absorbable interrupted sutures (eg, monocryl). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Repair of lacerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep or large vaginal lacerations may be repaired in one or more layers. Exploratory laparotomy or laparoscopy may be necessary for full evaluation of deep lacerations that extend through the posterior cul de sac and into the peritoneal cavity to rule out damage to internal organs. Diverting colostomy may be needed if the gastrointestinal tract is involved. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Repair of lacerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regarding management of hematomas, if possible, vulvar hematomas are managed conservatively with ice, analgesia, and pelvic rest. A Foley catheter is recommended if the hematoma is large since it often interferes with urination. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management of hematomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expansion of a vulvar or vaginal hematoma or a falling hematocrit are indications for prompt surgical intervention as persistent hemorrhage can lead to hemodynamic instability and other complications. If bleeding vessels are not ligated adequately before the edges are closed, another hematoma may develop. However, in many cases, the vessels cannot be identified so the incision is closed and a drain is left in place. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management of hematomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/1\">",
"      Bond GR, Dowd MD, Landsman I, Rimsza M. Unintentional perineal injury in prepubescent girls: a multicenter, prospective report of 56 girls. Pediatrics 1995; 95:628.",
"     </a>",
"    </li>",
"    <li>",
"     Merrit DF. Genital trauma. In: Pediatric &amp; Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Wolters Kluwer Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/3\">",
"      Kanai M, Osada R, Maruyama K, et al. Warning from Nagano: increase of vulvar hematoma and/or lacerated injury caused by snowboarding. J Trauma 2001; 50:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/4\">",
"      Merritt DF. Vulvar and genital trauma in pediatric and adolescent gynecology. Curr Opin Obstet Gynecol 2004; 16:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/5\">",
"      Okur H, K&uuml;&ccedil;&iuml;kaydin M, Kazez A, et al. Genitourinary tract injuries in girls. Br J Urol 1996; 78:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/6\">",
"      Virgili A, Bianchi A, Mollica G, Corazza M. Serious hematoma of the vulva from a bicycle accident. A case report. J Reprod Med 2000; 45:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/7\">",
"      Jana N, Santra D, Das D, et al. Nonobstetric lower genital tract injuries in rural India. Int J Gynaecol Obstet 2008; 103:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/8\">",
"      Goldberg J, Horan C, O'Brien LM. Severe anorectal and vaginal injuries in a jet ski passenger. J Trauma 2004; 56:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/9\">",
"      Niv J, Lessing JB, Hartuv J, Peyser MR. Vaginal injury resulting from sliding down a water chute. Am J Obstet Gynecol 1992; 166:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/10\">",
"      Smith BL. Vaginal laceration caused by water skiing. J Emerg Nurs 1996; 22:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/11\">",
"      Wilson F, Swartz DP. Coital injuries of the vagina. Obstet Gynecol 1972; 39:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/12\">",
"      Emans SJ, Woods ER, Flagg NT, Freeman A. Genital findings in sexually abused, symptomatic and asymptomatic, girls. Pediatrics 1987; 79:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/13\">",
"      Jones JS, Dunnuck C, Rossman L, et al. Significance of toluidine blue positive findings after speculum examination for sexual assault. Am J Emerg Med 2004; 22:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/14\">",
"      Parker JD, Hibbert ML, Dainty LD, et al. Micro-hydrovaginoscopy in examining children. Obstet Gynecol 2000; 96:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/15\">",
"      Goldman HB, Idom CB Jr, Dmochowski RR. Traumatic injuries of the female external genitalia and their association with urological injuries. J Urol 1998; 159:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/16\">",
"      Netto J&uacute;nior NR, Ikari O, Zuppo VP. Traumatic rupture of female urethra. Urology 1983; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/17\">",
"      Niemi TA, Norton LW. Vaginal injuries in patients with pelvic fractures. J Trauma 1985; 25:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/18\">",
"      Takayama T, Mugiya S, Ohira T, et al. Complete disruption of the female urethra. Int J Urol 1999; 6:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/19\">",
"      Friedel W, Kaiser IH. Vaginal evisceration. Obstet Gynecol 1975; 45:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/20\">",
"      Lal P, Mohan P, Sharma R, et al. Postcoital vaginal laceration in a patient presenting with signs of small bowel perforation: report of a case. Surg Today 2001; 31:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/21\">",
"      McColgin SW, Williams LM, Sorrells TL, Morrison JC. Hemoperitoneum as a result of coital injury without associated vaginal injury. Am J Obstet Gynecol 1990; 163:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/22\">",
"      Sadler DW, Pounder DJ. Fatal air embolism occurring during consensual intercourse in a non-pregnant female. J Clin Forensic Med 1998; 5:77.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Antibiotic Prophylaxis for Gynecologic Procedures. Clinical Management Guidelines for Obstetrician-Gynecologists, ACOG bulletin Number 24, American College of Obstetricians and Gynecologists, Washington DC 2001. p.268.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/24\">",
"      Minassian VA, Jazayeri A, Prien SD, et al. Randomized trial of lidocaine ointment versus placebo for the treatment of postpartum perineal pain. Obstet Gynecol 2002; 100:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/25\">",
"      Kettle C, Dowswell T, Ismail KM. Absorbable suture materials for primary repair of episiotomy and second degree tears. Cochrane Database Syst Rev 2010; :CD000006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/26\">",
"      Lundquist M, Olsson A, Nissen E, Norman M. Is it necessary to suture all lacerations after a vaginal delivery? Birth 2000; 27:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/27\">",
"      Dhulkotia JS, Alazzam M, Galimberti A. Tisseel for management of traumatic postpartum haemorrhage. Arch Gynecol Obstet 2009; 279:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/28\">",
"      Benrubi G, Neuman C, Nuss RC, Thompson RJ. Vulvar and vaginal hematomas: a retrospective study of conservative versus operative management. South Med J 1987; 80:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/29\">",
"      Gianini GD, Method MW, Christman JE. Traumatic vulvar hematomas. Assessing and treating nonobstetric patients. Postgrad Med 1991; 89:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/30\">",
"      Mok-Lin EY, Laufer MR. Management of vulvar hematomas: use of a Word catheter. J Pediatr Adolesc Gynecol 2009; 22:e156.",
"     </a>",
"    </li>",
"    <li>",
"     Sachs, PB. Women's diagnostic imaging, case fifteen: Factor II deficiency with vulvar hematoma. www.uhrad.com (Accessed on May 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/32\">",
"      Kunishima K, Takao H, Kato N, et al. Transarterial embolization of a nonpuerperal traumatic vulvar hematoma. Radiat Med 2008; 26:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/33\">",
"      Whiteside JL, Asif RB, Novello RJ. Fibrin sealant for management of complicated obstetric lacerations. Obstet Gynecol 2010; 115:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/34\">",
"      Harlow BL, Wise LA, Stewart EG. Prevalence and predictors of chronic lower genital tract discomfort. Am J Obstet Gynecol 2001; 185:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44071/abstract/35\">",
"      Munarriz R, Talakoub L, Somekh NN, et al. Characteristics of female patients with sexual dysfunction who also had a history of blunt perineal trauma. J Sex Marital Ther 2002; 28 Suppl 1:175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5449 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44071=[""].join("\n");
var outline_f43_2_44071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obstetrical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gynecological",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Perineum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PERIOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sedation/anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REPAIR OF LACERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vagina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Superficial lacerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Deep lacerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Extension beyond the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT OF HEMATOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FOLLOW UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5449\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5449|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/55/17268\" title=\"figure 1\">",
"      Second deg vag laceratio repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/24/28036\" title=\"figure 2\">",
"      Repair sphincter third degr lac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/39/42613\" title=\"figure 3\">",
"      Repair 4th degree laceration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5449|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/12/20676\" title=\"picture 1\">",
"      Vulva hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/28/37314\" title=\"picture 2A\">",
"      Vulva trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/57/19345\" title=\"picture 2B\">",
"      Vulva trauma drain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/57/26514\" title=\"picture 3\">",
"      Vulva hematoma and catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/39/629\" title=\"picture 4\">",
"      Ruptured vulva hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/20/20806\" title=\"picture 5\">",
"      Suction vulva hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/8/32899\" title=\"picture 6\">",
"      Vulva hematoma with drain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34263?source=related_link\">",
"      Delayed surgical management of the disrupted anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35669?source=related_link\">",
"      Straddle injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/1/16408?source=related_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_2_44072="ECG Antidromic AVRT";
var content_f43_2_44072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (EG) showing antidromic atrioventricular reentrant tachycardia (AVRT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG shows a wide complex tachycardia in a patient with Wolff-Parkinson-White syndrome and a left lateral accessory pathway. The QRS complexes are wide and have a morphology that is similar to that during sinus rhythm, confirming that this is an antidromic atrioventricular reentrant tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44072=[""].join("\n");
var outline_f43_2_44072=null;
var title_f43_2_44073="Disseminated neonatal HSV";
var content_f43_2_44073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Disseminated neonatal HSV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adrenals (A) and liver (B) of a neonate who died from disseminated neonatal herpes simplex virus (HSV) disease, showing hemorrhagic lesions on the adrenals and patchy white areas on the liver capsule. Microscopic histopathologic sections of the involved organs (C and D) showed coagulative necrosis, hemorrhage, and Cowley type A and B viral inclusion bodies, characteristic of HSV infection. Viral culture of the organs grew HSV type 2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Edwina Popek, MD, Megan Dishop, MD, Jenny Ravenscroft, MD, and Gail Demmler-Harrison, MD, Department of Pediatric Pathology, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44073=[""].join("\n");
var outline_f43_2_44073=null;
var title_f43_2_44074="Chemotherapy hepatotoxicity and dose modification in patients with liver disease";
var content_f43_2_44074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Justin Floyd, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Thomas Archibald Kerr, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/2/44074/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/2/44074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing cytotoxic chemotherapy require careful assessment of liver function both prior to and during therapy. Potential interactions between the liver and chemotherapy fall into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct chemotherapy-induced hepatotoxicity.",
"     </li>",
"     <li>",
"      Potentiation of preexisting liver disease, especially viral hepatitis. Altered hepatic drug metabolism due to underlying liver disease can result in higher or more persistent drug levels, thereby causing increased systemic toxicity (particularly myelosuppression) or worsening of liver function because of chemotherapy-induced hepatotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interrelationship between the liver and chemotherapy is reviewed here. General aspects of drug metabolism and patterns of hepatic injury are discussed separately as is reactivation of hepatitis B viral infection in patients treated with immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ASPECTS OF DRUG-INDUCED HEPATOTOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most hepatotoxic drug reactions are idiosyncratic and classified mechanistically either as immunologic (hypersensitivity) or metabolic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/1\">",
"     1",
"    </a>",
"    ]. These reactions typically are neither dose-dependent nor predictable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13754?source=see_link&amp;anchor=H14#H14\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\", section on 'Mechanisms of drug-induced hepatotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the reaction to many chemotherapy drugs is manifested by hepatocellular injury, inflammation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholestasis, other agents cause endothelial damage or thrombosis leading to vascular complications such as hepatic veno-occlusive disease (also called hepatic sinusoidal obstruction syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2739719\">",
"    <span class=\"h3\">",
"     Liposomal drug formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liposomal drug delivery systems have been utilized to improve the pharmacologic characteristics of chemotherapeutics and antibiotics, and improve drug deliver to optimal sites of action. Nevertheless, concerns have been raised about altered toxicity profiles with these preparations relative to non-encapsulated drug forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case control study of patients undergoing hematopoietic cell transplant, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      was associated with a",
"      <strong>",
"       higher",
"      </strong>",
"      rate of elevated liver enzymes compared with conventional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (AMB-D) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/2\">",
"       2",
"      </a>",
"      ]. However, an autopsy study of 64 patients treated before death with either liposomal amphotericin B (L-AMB) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      (ABLC) failed to reveal any clear histologic evidence of hepatotoxicity in either group, despite well characterized elevations in liver enzymes with administration of these medicines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/3\">",
"       3",
"      </a>",
"      ]. These data suggest that elevated liver enzymes associated with liposomal drug formulations such as amphotericin B may not reflect severe histologic injury.",
"     </li>",
"     <li>",
"      On the other hand, animal studies have suggested that sterically stabilized liposomal encapsulation of 6-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      is associated with decreased hepatoxicity compared with conventional liposomal formulations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As liposomal drug delivery approaches become more common and diverse, patterns of hepatotoxicity may be altered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Hepatic vascular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic sinusoidal obstruction syndrome (SOS), previously called hepatic veno-occlusive disease (VOD), is a pattern of liver injury that is caused by nonthrombotic obliteration of small intrahepatic veins by subendothelial fibrin. SOS is associated with congestion and potentially fatal necrosis of centrilobular hepatocytes.",
"   </p>",
"   <p>",
"    SOS occurs most frequently in patients undergoing hematopoietic cell transplantation. Most cases are thought to be drug-induced, and the drugs most commonly implicated are those that undergo hepatic metabolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7081?source=see_link\">",
"     \"Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SOS has occasionally been reported with non-myeloablative doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (DTIC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/5-11\">",
"     5-11",
"    </a>",
"    ], including patients treated with ABVD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , dacarbazine) for Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], and with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/11\">",
"     11",
"    </a>",
"    ], 6-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    or 6-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pattern of hepatic vascular injury similar to that seen in SOS has been noted in patients receiving combinations of 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for neoadjuvant (downstaging) therapy prior to the resection of colorectal cancer liver metastases. Findings at the time of liver resection include steatosis, hepatic vascular injury, and nodular regenerative hyperplasia. Because of this injury pattern, it is generally recommended that the duration of neoadjuvant therapy be limited to the fewest number of cycles needed to render patients resectable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H5842613#H5842613\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Chemotherapy-related liver toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Irradiation plus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although radiation to the liver is itself hepatotoxic, otherwise tolerable doses of radiation therapy to the right upper quadrant can induce severe hepatic injury when combined with systemic doses of normally nonhepatotoxic chemotherapeutic agents. This has been described most often in patients treated concurrently with hepatic radiation and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/18,19\">",
"     18,19",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/20\">",
"     20",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H31\">",
"     'Dactinomycin'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In an illustrative series, 35 patients with lymphoma received concurrent monthly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and relatively low-dose liver irradiation (total dose, 15 to 25 Gy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/18\">",
"     18",
"    </a>",
"    ]. Ten of 35 patients developed severe hepatotoxicity (AST greater than three times normal, clinical evidence of liver failure, one fatal), and nine had moderate toxicity.",
"   </p>",
"   <p>",
"    Reactivation or exacerbation of radiation-induced hepatic damage is a likely mechanism, since all of these drugs have been associated with a radiation \"recall\" reaction in previously irradiated tissues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H20#H20\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Radiation recall and enhancement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of chemotherapy-related hepatotoxicity can range from asymptomatic biochemical abnormalities to an acute illness with jaundice that resembles viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of liver injury is primarily assessed by measurement of the serum aminotransferases (AST and ALT), bilirubin, and alkaline phosphatase. The pattern of abnormalities on these tests is more informative than elevation of any individual test. Elevation of aminotransferases (AST, ALT) typically indicates hepatocellular injury, while increases in bilirubin and alkaline phosphatase suggest cholestasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/63/21494?source=see_link\">",
"     \"Liver biochemical tests that detect injury to hepatocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standardized criteria have been developed by the National Cancer Institute (NCI) and World Health Organization (WHO) to quantify or grade the severity of treatment-related abnormalities in the liver function tests (LFTs) in patients undergoing chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef77533 \" href=\"mobipreview.htm?37/40/38540\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The distinction between drug-induced hepatotoxicity due to chemotherapy and other causes of liver injury can be difficult.",
"   </p>",
"   <p>",
"    The differential diagnosis includes progressive tumor, coexisting hepatic disease, and adverse effects of other drugs which produce similar clinical features and abnormalities in the LFTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Features suggesting toxicity due to chemotherapy include lack of prior illness, clinical symptoms or biochemical abnormalities developing after drug administration, and improvement after discontinuation of the cytotoxic agent.",
"   </p>",
"   <p>",
"    Abdominal ultrasound or computed tomography (CT) may be needed to differentiate drug toxicity from biliary, vascular, or tumor-related conditions. A liver biopsy is seldom necessary to characterize or stage acute hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of chemotherapy hepatotoxicity is variable. Some agents cause reversible toxicity while others are associated with a progressive course that can lead to fibrosis or cirrhosis despite drug discontinuation. Toxicity will generally recur upon reintroduction of the offending substance if the reaction was immunologically based. In this situation, rechallenge is usually not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Impact of preexisting liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility to chemotherapy-induced liver injury may be increased by the presence of hepatobiliary metastases, immune compromise,",
"    <span class=\"nowrap\">",
"     viral/autoimmune",
"    </span>",
"    hepatitis, nutritional deficiencies, or the use of parenteral nutrition.",
"   </p>",
"   <p>",
"    Patients with a preexisting liver disease should undergo a full diagnostic workup prior to chemotherapy to elucidate the cause and severity of the liver disease. Therapy of any coexisting liver disorder should be optimized to minimize the potential for chemotherapy-induced complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical decision-making must incorporate the need for expedient treatment of the patient's malignancy. Some drugs will need to be avoided while dose reduction may be appropriate for other agents in patients with significant liver disease, regardless of its etiology.",
"   </p>",
"   <p>",
"    Infection with hepatitis B (HBV) or hepatitis C (HCV) is a common disorder that can be exacerbated with cytotoxic chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports have documented an increased incidence of HBV reactivation in patients receiving systemic chemotherapy, particularly in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/25\">",
"     25",
"    </a>",
"    ]. At least one study suggests that a high viral load prior to treatment is an adverse factor for survival and may be associated with a higher incidence of severe hepatitis during chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, a growing number of studies have demonstrated that prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    can reduce both the incidence of reactivation and its severity in patients who are HBsAg positive. The American Association for the Study of Liver Diseases has published guidelines for evaluation and treatment of patients with chronic HBV infection, including recommendations regarding antiviral prophylaxis for hepatitis B-infected patients undergoing chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link&amp;anchor=H5#H5\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Cancer chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link&amp;anchor=H13#H13\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link&amp;anchor=H15#H15\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Major society guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although severe hepatitis from reactivation of HCV infection has been documented in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], it seems to be less common than HBV activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/25\">",
"     25",
"    </a>",
"    ], and the relationship between immunosuppressive chemotherapy and viral reactivation is less clear than for HBV.",
"   </p>",
"   <p>",
"    In three large series of patients who had anti-HCV antibodies, treatment for hematologic malignancies was associated with mild LFT abnormalities in 18 percent or fewer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In another report of 33 patients, 32 of whom had chronic disease as manifested by positivity for HCV RNA, transaminases increased in 55 percent; however, only one patient had a severe flare of underlying hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, although chemotherapy may be associated with elevations in LFTs in patients with HCV, this does not appear to be a major issue except for those with evidence of a chronic infection.",
"   </p>",
"   <p>",
"    Infection with HCV does appear to increase the risk of developing SOS in patients undergoing high dose chemotherapy and hematopoietic stem cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\", section on 'Hepatitis C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CYTOTOXIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered drug metabolism due to hepatic dysfunction can result in systemic toxicity due to higher or more persistent drug levels. Knowledge of the pharmacokinetics of antineoplastic agents in patients with liver disease is incomplete and has generally been derived from small numbers of heterogeneous patients with only mild to moderate liver dysfunction. As a result, guidelines for dose adjustment are largely empirical (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dose adjustments must be viewed in the appropriate clinical context. Patients with metastatic disease are rarely cured, and initial chemotherapy doses that could lead to excessive treatment-related toxicity should be avoided. If LFTs are abnormal because of extensive liver metastases, and the hepatic metastases respond to treatment, doses can often be increased after the initial courses of therapy.",
"   </p>",
"   <p>",
"    In this section, both the hepatotoxicity of specific chemotherapy agents and recommended dose modifications due to altered hepatic metabolism are discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alkylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, alkylating agents are uncommonly associated with hepatotoxicity. Although the mechanism of liver damage associated with these agents is unclear, depletion of glutathione and oxidative injury have been implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/35\">",
"     35",
"    </a>",
"    ]. With the possible exception of cyclophosphamide and ifosfamide, patients receiving alkylating agents usually do not require dose reduction because of underlying liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is metabolized by the liver to 4-hydroxycyclophosphamide, which is in equilibrium with its acyclic tautomeric form, aldophosphamide. In susceptible cells, nonenzymatic cleavage of aldophosphamide yields phosphoramide mustard and acrolein, which are thought to be the cytotoxic metabolites.",
"   </p>",
"   <p>",
"    Despite its conversion in the liver to an active metabolite,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is infrequently hepatotoxic. Abnormal LFTs attributed to the drug have only been reported occasionally, and this effect is probably due to an idiosyncratic reaction rather than direct toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients undergoing treatment for vasculitis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has been associated with liver necrosis when its administration was preceded by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/41\">",
"     41",
"    </a>",
"    ]. In two of the four affected patients, cyclophosphamide had previously been administered as a single agent without hepatic injury, suggesting that an interaction between the drugs was responsible for this toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased toxicity has not been reported in patients with hepatic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Nevertheless, some clinicians recommend a 25 percent dose reduction in dose for patients with a serum bilirubin 3.1 to 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or aspartate transaminase (AST) &gt; three times the upper limit of normal (ULN), and not giving the drug if the bilirubin is &ge;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44\">",
"     44",
"    </a>",
"    ]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US Food and Drug Administration (FDA)-approved manufacturer's product labeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    has been uncommonly associated with hepatotoxicity; in a total of 2070 patients from 30 studies of single agent ifosfamide, the reported incidence of liver dysfunction was 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose reductions are probably not necessary for patients with altered liver function. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    is extensively hepatically metabolized and some clinicians recommend a 25 percent dose reduction for patients with significant hepatic dysfunction (serum AST &gt;300",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    or bilirubin &gt;3",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44,47\">",
"     44,47",
"    </a>",
"    ]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other alkylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other alkylating agents generally are not dependent upon the liver for the metabolism and are not frequently associated with hepatotoxicity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nitrogen mustard &mdash; Nitrogen mustard is rapidly degraded and does not require hepatic metabolism for its disposition. Nitrogen mustard has not been associated with hepatotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       Melphalan",
"      </a>",
"      &mdash; Melphalan is rapidly hydrolyzed in plasma, and approximately 15 percent is excreted unchanged in the urine; the remainder is metabolized and excreted in stool. Although melphalan is not associated with hepatotoxicity at usual oral doses, transient LFT abnormalities have been reported with the higher doses used in the setting of hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"       \"Preparative regimens for hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       Chlorambucil",
"      </a>",
"      &mdash; Chlorambucil rarely causes hepatotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. In one autopsy series of 181 patients with hematologic malignancies, three of six cases of cholestatic jaundice were attributed to chlorambucil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/51\">",
"       51",
"      </a>",
"      ]. In a second case report, drug-induced hepatotoxicity and skin rash recurred upon rechallenge with chlorambucil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       Busulfan",
"      </a>",
"      &mdash; Busulfan is rapidly cleared from the blood after intravenous administration and almost entirely excreted in the urine as methanesulfonic acid; hepatic metabolism is unimportant. At standard doses, busulfan rarely causes hepatic dysfunction, although it has been linked to some cases of cholestatic hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Busulfan is a common component of preparative regimens for hematopoietic cell transplantation. In this setting, busulfan has been associated with hepatic SOS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link\">",
"       \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"       Bendamustine",
"      </a>",
"       Bendamustine undergoes hepatic metabolism, and the manufacturer recommends that the drug not be administered to patients with preexisting moderate to severe hepatic impairment (transaminases &ge;2.5X ULN or total bilirubin &ge; 1.5 X ULN). &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       Temozolomide",
"      </a>",
"      &mdash; Temozolomide is an orally active alkylating agent. Patients with mild to moderate hepatic dysfunction have similar pharmacokinetics compared to those with normal function, although patients with severe hepatic dysfunction have not been studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/55\">",
"       55",
"      </a>",
"      ]. Temozolomide rarely causes cholestatic liver injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/56-58\">",
"       56-58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nitrosoureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nitrosoureas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    (BCNU),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    (CCNU), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    appear to function as both alkylating and carbamoylating agents. Like other alkylating agents, nitrosoureas deplete hepatic stores of glutathione [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/59\">",
"     59",
"    </a>",
"    ], which may increase the risk of oxidative injury.",
"   </p>",
"   <p>",
"    Increases in LFTs occur in 20 to 25 percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    -treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], and the onset may be delayed up to four months following treatment. At conventional doses, LFT elevations are usually mild and revert to normal over a brief period, although fatalities have been reported. The hepatotoxic effects of CCNU are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     Streptozocin",
"    </a>",
"    -induced hepatotoxicity is manifest primarily as hepatocellular injury and has been reported in 15 to 67 percent of treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. These changes appear within a few days to weeks after treatment and are usually asymptomatic; rapid, complete resolution is the rule.",
"   </p>",
"   <p>",
"    Although dosing adjustment may be necessary in patients with severe hepatic dysfunction, no guidelines have been published for any of the nitrosoureas. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling. Hepatic function should be closely monitored during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antimetabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatotoxic potential of antimetabolites is variable. Hepatic metabolism plays an important role in the disposition of many drugs in this class, and dose reduction is frequently necessary in patients with liver dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    has been difficult to establish because it is used for treatment of leukemia, and these patients frequently undergo transfusions of blood products, are subject to infections, receive multiple medications, and are often not candidates for liver biopsy because of prolonged thrombocytopenia. Abnormal LFTs were reported in 37 of 85 leukemic patients receiving cytarabine in an early series, but many patients had preexisting LFT abnormalities, potentially confounding factors (eg, sepsis or hemolysis), or spontaneous resolution of biochemical abnormalities despite continuation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In more contemporary reports,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    infrequently causes histologically proven cholestasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Furthermore, transiently abnormal LFTs developed in 24 of 27 patients undergoing high-dose cytarabine by 72 hour continuous infusion in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/68\">",
"     68",
"    </a>",
"    ]. These effects are reversible and generally not dose-limiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The liver is the primary site for the detoxification of much of the administered dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    . Doses should be reduced in patients with severe hepatic dysfunction, in order to avoid an increased risk of treatment-related central nervous system toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H28#H28\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians recommend a 50 percent decrease in the dose in patients with any aminotransferase elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44\">",
"     44",
"    </a>",
"    ]. However, this is not routinely done in potentially curative settings such as induction therapy for acute myelogenous leukemia. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Fluorouracil and capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following intravenous administration, approximately 10 percent of administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) is excreted unchanged in the urine, while the remainder is catabolized by dihydropyrimidine dehydrogenase (DPD), primarily in the liver. Both the toxicity and the antitumor effect are potentiated if catabolism is blocked by inhibition or inactivity of DPD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only rare reports of hepatotoxicity have been noted with 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/72\">",
"     72",
"    </a>",
"    ]. More hepatotoxicity has been reported when 5-FU is administered in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Hepatic vascular injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is a fluoropyrimidine that is absorbed through the intestinal wall and then metabolized to the active metabolite, 5-FU. Capecitabine causes hyperbilirubinemia, but this is sometimes attributable to hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the liver's role in the catabolism of intravenous 5-FU, some clinicians recommend that doses be omitted in patients with liver failure (serum bilirubin &gt;5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44\">",
"     44",
"    </a>",
"    ]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling. In contrast, the pharmacology of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is not significantly affected by liver dysfunction, and dose reduction is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Floxuridine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 5-FU metabolite",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    (fluorodeoxyuridine, FUdR) is administered via the hepatic artery, usually for patients with isolated liver metastases from colorectal carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=see_link&amp;anchor=H11#H11\">",
"     \"Nonsurgical local treatment strategies for colorectal cancer liver metastases\", section on 'Hepatic intraarterial chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarterial FUdR is associated with significant dose-limiting liver toxicity. Hepatic damage can be manifested in two ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatocellular injury with increased",
"      <span class=\"nowrap\">",
"       AST/ALT,",
"      </span>",
"      alkaline phosphatase, and serum bilirubin (hepatitis pattern)",
"     </li>",
"     <li>",
"      Biliary sclerosis, which results either from toxic effects on the biliary system or ischemic changes secondary to fibrosis of the pericholangitic venous plexus, both of which can result in stricture of the bile ducts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/80-85\">",
"       80-85",
"      </a>",
"      ]. The incidence ranges from 1 to 26 percent. Stricture of the intrahepatic or extrahepatic bile ducts is accompanied by elevated alkaline phosphatase and serum bilirubin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    FUdR-related hepatotoxicity appears to be both time- and dose-dependent. With rare exception, the hepatitis pattern improves with the temporary cessation of chemotherapy; however, secondary biliary sclerosis is irreversible (although treatable with stenting or dilatation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Two patterns of sclerosis may be evident: a diffuse pattern or a diffuse pattern with short segments of tight stricture, which are usually located in the proximal bile ducts.",
"   </p>",
"   <p>",
"    LFTs should be checked at least weekly during therapy with intrahepatic arterial FUdR and drug administration discontinued (ie, the pump emptied) when hepatic toxicity becomes evident. Treatment should be restarted only when toxicity has resolved. Dose adjustment guidelines for FUdR in this setting have been published (",
"    <a class=\"graphic graphic_table graphicRef67680 \" href=\"mobipreview.htm?9/6/9325\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/88\">",
"     88",
"    </a>",
"    ]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    is commonly associated with a transient rise in serum aminotransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/89\">",
"     89",
"    </a>",
"    ], but these are seldom of clinical significance; liver failure and death are very rare. There are case reports of rare fatal cholestatic hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited and conflicting data about",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    dosing in patients with preexisting liver dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 18 patients with preexisting liver dysfunction who were enrolled into a phase I trial of escalating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      doses, giving gemcitabine to patients with preexisting hyperbilirubinemia (bilirubin levels &gt;1.6",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      led to further deterioration in liver function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/91\">",
"       91",
"      </a>",
"      ]. The authors recommended an empiric initial dose reduction to 800 rather than 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      in this setting.",
"     </li>",
"     <li>",
"      On the other hand, a case series of seven patients who received at least one dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      when their serum bilirubin level was &ge;4.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      suggests that the full dose of gemcitabine can be given safely in patients with severe hepatic dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/92\">",
"       92",
"      </a>",
"      ]. Only one patient had a platelet count below 100,000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      that warranted reduction or withholding of a dose and no patient had a further deterioration of liver function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific dosing guidelines for patients with hepatic insufficiency are not provided in the US FDA-approved manufacturer's product labeling. However, it is probably prudent to utilize at least a 20 percent dose reduction for patients with hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/93\">",
"     93",
"    </a>",
"    ]. In the absence of toxicity, dose re-escalation could be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Mercaptopurine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity related to the purine analog 6-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6MP) is most common if the usual daily dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is exceeded. Two patterns have been noted: cholestatic liver damage and hepatocellular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/94-98\">",
"     94-98",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with cholestasis, histologic features include bland cholestasis, with minimal hepatic necrosis but significant cytologic atypia and disorganized hepatic cords [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/97,98\">",
"       97,98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatocellular injury typically occurs more than 30 days after treatment initiation. Moderate elevations in serum transaminases and alkaline phosphatase are accompanied by serum bilirubin levels between 3 and 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Changing the route of administration from oral to intravenous does not alter the pattern of hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/99\">",
"     99",
"    </a>",
"    ]. Spontaneous resolution generally follows drug discontinuation.",
"   </p>",
"   <p>",
"    Hepatotoxicity is thought to be a direct toxic effect of 6MP, because rechallenge does not necessarily shorten the latent period, and systemic manifestations of hypersensitivity (eg, rash, arthralgias, and eosinophilia) are usually not present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/95\">",
"     95",
"    </a>",
"    ]. However, in a series of 396 patients treated with 6MP (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for an average of 60 months) for refractory inflammatory bowel disease, hepatitis developed in only one, and liver biopsy suggested a hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/100\">",
"     100",
"    </a>",
"    ]. Hepatotoxicity has been described in patients treated with the combination of standard dose 6-MP and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H55\">",
"     'Combination chemotherapy regimens'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    6MP is metabolized in the liver by xanthine oxidase. Although specific guidelines are not available, dose reduction should be considered in patients with severe liver dysfunction to prevent drug accumulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZ), a nitroimidazole derivative of 6-MP, is used as an immunosuppressive agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatotoxicity is less frequent, milder, and less dose-dependent compared to 6-MP. Three different patterns of hepatotoxicity have been reported: hypersensitivity, an idiosyncratic cholestatic reaction, and presumed endothelial cell injury, with raised portal pressures, sinusoidal obstruction syndrome (SOS) or peliosis hepatis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/102\">",
"     102",
"    </a>",
"    ]. Most reports of SOS have been observed in the setting of renal or hepatic transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Hepatic vascular injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cholestatic injury is characterized by an increased serum bilirubin and alkaline phosphatase, with moderate elevations in",
"    <span class=\"nowrap\">",
"     AST/ALT,",
"    </span>",
"    and by variable degrees of parenchymal cell necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. It is speculated that patients who develop hepatotoxicity convert AZ into 6-MP at an unusually rapid rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/105\">",
"     105",
"    </a>",
"    ], an example of genetically-determined host metabolic idiosyncrasy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Thioguanine",
"    </span>",
"    &nbsp;&mdash;&nbsp;6-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/54/35685?source=see_link\">",
"     Thioguanine",
"    </a>",
"    (6-TG) has been implicated in the development of hepatic SOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/14,106-108\">",
"     14,106-108",
"    </a>",
"    ] and in a single case of peliosis hepatis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/109\">",
"     109",
"    </a>",
"    ]. An early report described jaundice among the potential adverse reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/110\">",
"     110",
"    </a>",
"    ]. TG is rapidly and extensively metabolized in the liver. Thus dose reduction or avoidance is recommended in patients with hepatic disease, although formal guidelines are lacking. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Hepatic vascular injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is a frequent component of combination chemotherapy regimens and is also used to treat a variety of nonmalignant disorders.",
"   </p>",
"   <p>",
"    MTX-induced hepatotoxicity in patients receiving the drug parenterally for treatment of cancer usually takes the form of an acute transaminitis. This is most common in patients receiving high dose MTX, which causes acute transaminitis in as many as 60 to 80 percent of patients; levels typically return to baseline within one to two weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link&amp;anchor=H11#H11\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Hepatotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, patients undergoing chronic low-dose MTX therapy for rheumatoid arthritis or psoriasis are at risk for cirrhosis and fibrosis. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are at least three case reports of hepatocellular carcinoma developing in patients with MTX-induced hepatic fibrosis, all of which were in children treated for ALL, one in a patient heterozygous for alpha-1 antitrypsin deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. These data suggest a potential for long-term carcinogenesis following treatment with MTX, at least in the rare patient who develops hepatic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=see_link\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In low doses, MTX is excreted mainly unchanged in the urine, while in high doses (such as are used to treat osteosarcoma, and CNS lymphoma), it is partially metabolized by the liver to 7-hydroxymethotrexate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/114\">",
"     114",
"    </a>",
"    ]. Specific dosing guidelines for hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling. Some clinicians suggest a 25 percent dose reduction for patients with either serum bilirubin 3.1 to 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or aminotransferases &gt;3X ULN, and omission of the drug for higher bilirubin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any third-space fluid (eg, ascites, pleural effusions) will accumulate MTX and act as a reservoir for slow distribution into the plasma, increasing the risk of toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/115\">",
"     115",
"    </a>",
"    ]. Large pleural or peritoneal effusions should be drained prior to therapy (particularly with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), and if this not possible, dose reduction is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10245190\">",
"    <span class=\"h3\">",
"     Pemetrexed and pralatrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/43/29366?source=see_link\">",
"     pralatrexate",
"    </a>",
"    are novel folate analogs used in the treatment of lung cancer and refractory T-cell lymphomas, respectively. There are no published guidelines to guide dose reductions for patients with preexisting hepatic dysfunction. However, both drugs are potentially hepatotoxic, and guidelines for dose reduction for patients who develop grade 3 or 4 treatment-related hepatotoxicity during treatment are available in the US FDA-approved manufacturer&rsquo;s package inserts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      , reduce dose by 75 percent for bilirubin elevation &gt;3 x ULN or transaminase elevation &gt;5 x ULN.",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/43/29366?source=see_link\">",
"       pralatrexate",
"      </a>",
"      , if total bilirubin &gt;3 to 10 x ULN, or transaminases &gt;5 to 20 x ULN, omit dose; after recovery to &le;grade 2 toxicity, decrease dose to 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      For bilirubin &gt;10 x ULN or transaminases &gt;20 x ULN, discontinue treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Antitumor antibiotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anthracyclines include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (free and liposome-encapsulated),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    (free and liposome-encapsulated),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    . Doxorubicin is the most widely studied of these agents; the other compounds appear to be metabolized similarly and have a comparable pattern of toxicity.",
"   </p>",
"   <p>",
"    Isolated case reports have suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    can cause increased aminotransferases and hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/116\">",
"     116",
"    </a>",
"    ]. However, these have generally been in the context of acute leukemia, where multiple factors may have contributed to hepatic dysfunction, or in patients undergoing right upper quadrant irradiation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Irradiation plus chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    is extensively metabolized in the liver; approximately 80 percent of each dose is excreted in bile. Patients with cholestasis have delayed clearance of doxorubicin and its metabolites and greater systemic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/117-119\">",
"     117-119",
"    </a>",
"    ]. In contrast, patients with cirrhosis or isolated aminotransferase elevation may have normal drug clearance; excess toxicity has been reported from standard doses in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/120,121\">",
"     120,121",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/122\">",
"     122",
"    </a>",
"    ], studies.",
"   </p>",
"   <p>",
"    Approaches to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    dosing in patients with impaired liver function are variable (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44,71,122-124\">",
"     44,71,122-124",
"    </a>",
"    ]. The US Food and Drug Administration (FDA)-approved labeling for doxorubicin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    recommend a 50 percent dose reduction for bilirubin 1.2 to 3",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and a 75 percent dose reduction for bilirubin 3.1 to 5",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Others suggest omission of the drug for bilirubin &gt;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44,93\">",
"     44,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The applicability of these guidelines to weekly schedules of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    administration is uncertain. In one report, weekly administration was well tolerated in a woman with hepatic metastases from breast cancer and hyperbilirubinemia; treatment led to symptomatic improvement and normalization of liver function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US FDA-approved labeling for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    , and liposome-encapsulated daunorubicin also recommends dose reduction for patients with serum bilirubin levels &ge;1.2",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and for epirubicin, a dose reduction for aminotransferase levels &gt;2X ULN (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ). Others have suggested dose modification for epirubicin based upon serum AST and the desired drug exposure level, but measurement of drug levels is not a common practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific recommendations are not available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    , although the FDA approved labeling suggests that a dose reduction be considered in patients with hepatic impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Mitoxantrone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     Mitoxantrone",
"    </a>",
"    is an anthraquinone that is structurally related to the anthracyclines. In patients with leukemia, transient elevations in aminotransferase levels have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/127,128\">",
"     127,128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total body drug clearance is reduced in patients with altered liver function, particularly hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/129-131\">",
"     129-131",
"    </a>",
"    ]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling. Some clinicians recommend a 50 percent dose reduction (or a dose of 14",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    for moderate dysfunction (bilirubin 1.5 to 3",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and a 75 percent dose reduction (or dose of 8",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    in those with a bilirubin level &gt;3.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Bleomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of each administered dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is excreted unchanged in the urine; the remainder is inactivated by an aminopeptidase that is present in many tissues, including liver. Most studies report a low incidence of liver dysfunction in patients receiving bleomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. One review of over 1000 treated patients concluded that hepatotoxicity was inconsistently reported, and no specific pattern could be ascribed to this drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Mitomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hepatotoxicity is rare in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    , drug-induced alterations in LFTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/134\">",
"     134",
"    </a>",
"    ], and hepatic sinusoidal obstruction syndrome (SOS) in the setting of high dose therapy with hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/135\">",
"     135",
"    </a>",
"    ] have been reported.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     Mitomycin",
"    </a>",
"    is metabolized predominantly in the liver; less than 10 percent is excreted unchanged in the urine, and biliary excretion also accounts for some elimination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/136\">",
"     136",
"    </a>",
"    ]. However, there are conflicting data regarding the influence of hepatic function on mitomycin clearance. In one report of 30 patients treated with mitomycin, there was no relationship between abnormal liver function, elimination half-life, and total body clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/137\">",
"     137",
"    </a>",
"    ]. Others have documented increased myelotoxicity in patients with preexisting hepatic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling. A number of different approaches have been utilized in patients with neoplasia-related hepatic dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of women with advanced breast cancer and a predominance of visceral disease, initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      doses were empirically adjusted for liver dysfunction as follows: bilirubin 1.5 to 3",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      50 percent of dose; bilirubin &gt;3.1",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      25 percent of dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/139\">",
"       139",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report, the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      was empirically decreased by 50 percent in patients with a serum bilirubin &gt;3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or hepatic enzymes &gt;3 times the upper limit of normal (ULN) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/140\">",
"       140",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Dactinomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     Dactinomycin",
"    </a>",
"    can cause a transient elevation in aminotransferases, which has most commonly occurred in children who received prior radiotherapy to the right upper quadrant. In this setting, greater than anticipated leukopenia and thrombocytopenia have also occurred, suggesting prolonged drug excretion due to radiation-induced hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/141\">",
"     141",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Irradiation plus chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hepatotoxicity also occurs in unirradiated patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    , and appears to be schedule dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. In one series of patients with Wilms' tumor receiving dactinomycin either on five consecutive days or a double dose on a single day, hepatotoxicity developed in 13 versus 0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A hepatopathy-thrombocytopenia syndrome (HTS) has been described in approximately 1 percent of children treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    for Wilms' tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/11\">",
"     11",
"    </a>",
"    ]. Hepatic venoocclusive disease is also reported. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Hepatic vascular injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling. A 50 percent reduction of dose has been recommended by some clinicians (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Dacarbazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several reports of hepatic vascular toxicity in adults with melanoma who received single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    . Clinical findings include acute hepatic failure, shock, and death within a few days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/144\">",
"     144",
"    </a>",
"    ]. Histologically, acute thrombotic occlusions are present involving the small and medium-sized veins, unlike classic nonthrombotic SOS. Eosinophilia and eosinophilic infiltrates are frequently present, suggesting an idiosyncratic hypersensitivity mechanism rather than direct endoluminal damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/5,144\">",
"     5,144",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Hepatic vascular injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     Dacarbazine",
"    </a>",
"    (DTIC) is metabolized by the hepatic microsomal pathway. Although patients with abnormal liver function may be at increased risk for hematologic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/71\">",
"     71",
"    </a>",
"    ], standard guidelines are not available for dose reduction in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Tubulin-acting agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic drugs that act upon tubulin and microtubules require dose reduction in the setting of hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Vinca alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient abnormalities in LFTs have been seen following treatment with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/145\">",
"     145",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/146\">",
"     146",
"    </a>",
"    ]. More severe hepatotoxicity is reported in patients who received vincristine plus concurrent irradiation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Irradiation plus chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The vinca alkaloids are metabolized primarily by the liver, and the bile is the main route of excretion. Liver dysfunction that is severe enough to raise the serum alkaline phosphatase and alter biliary excretion results in delayed clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    with a greater potential for toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44,71,147,148\">",
"     44,71,147,148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US FDA-approved labeling information recommends that the dose of either agent be reduced by 50 percent in patients with a serum bilirubin &gt;3",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Other guidelines for dosing adjustments have been recommended by some clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44,93\">",
"     44,93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum bilirubin 1.5 to 3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or aminotransferases two to three times the ULN &mdash; Administer 50 percent of normal dose",
"     </li>",
"     <li>",
"      Serum bilirubin &gt;3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or aminotransferases &gt;3 times the ULN &mdash; Omit dose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is less information available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    . The US FDA-approved labeling information recommends a 50 percent dose reduction for patients who develop moderate liver dysfunction during therapy (total bilirubin 2.1 to 3.0",
"    <span class=\"nowrap\">",
"     ng/dL),",
"    </span>",
"    and a 75 percent dose reduction for more severe hyperbilirubinemia (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ). Others suggest that dose modification may not be necessary with mild to moderate liver impairment (total bilirubin &lt;3 times ULN, transaminases &lt;2.5 times ULN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/149,150\">",
"     149,150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    is not usually hepatotoxic at standard doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/151\">",
"     151",
"    </a>",
"    ], although at least one report documents severe hepatocellular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/152\">",
"     152",
"    </a>",
"    ]. At high doses, etoposide has been associated with hyperbilirubinemia and elevated transaminases and alkaline phosphatase levels approximately three weeks after administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/153,154\">",
"     153,154",
"    </a>",
"    ]. These abnormalities cleared without sequelae over 12 weeks.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    is extensively (97 percent) protein bound, and 70 to 80 percent of drug is eliminated through nonrenal mechanisms, presumably liver metabolism and bile excretion. Elevated serum bilirubin levels have been correlated with decreased clearance and enhanced leukopenia in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/155,156\">",
"     155,156",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/157-159\">",
"     157-159",
"    </a>",
"    ] studies. Others suggest that patients with increased bilirubin have an increased exposure to unbound drug, but without a reduction in total systemic clearance of the drug, possibly because of enhanced renal clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/158,160,161\">",
"     158,160,161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific dosing guidelines for patients with hepatic insufficiency are not available in the US Food and Drug Administration (FDA)-approved manufacturer's product labeling. Some clinicians recommend a 50 percent dose reduction for patients with a serum bilirubin 1.5 to 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or AST &gt;3 times the ULN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44,93\">",
"     44,93",
"    </a>",
"    ], and reduction or omission of the dose for higher bilirubin levels.",
"   </p>",
"   <p>",
"    Low albumin levels (&lt;3.5",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    are associated with an increase in the fraction of free drug, and this may lead to more pronounced hematologic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/162,163\">",
"     162,163",
"    </a>",
"    ]. A dose reduction by 33 or 50 percent has been recommended for patients with a reduced serum albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/93,162\">",
"     93,162",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Taxanes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H714826\">",
"    <span class=\"h4\">",
"     Paclitaxel and docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with normal baseline LFTs who are treated with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , transient elevations of alkaline phosphatase, AST, and bilirubin have been reported in about 5 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/164\">",
"     164",
"    </a>",
"    ]. Hepatic toxicity is not dose-dependent, and prolonged exposure to taxanes is not associated with cumulative hepatic toxicity.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    undergo oxidation by the hepatic cytochrome P450 system and are excreted in the bile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/165,166\">",
"     165,166",
"    </a>",
"    ]. Clinically significant interactions have been reported with other drugs that are metabolized by cytochrome P450, including inhibitors and inducers of CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/167\">",
"     167",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with slightly elevated alkaline phosphatase or aminotransferases have decreased",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    clearance and are at increased risk for severe treatment-related toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/168,169\">",
"     168,169",
"    </a>",
"    ]. The impact of hepatic dysfunction on paclitaxel clearance varies depending upon the duration of drug infusion and the extent of liver abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/170-172\">",
"     170-172",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US FDA-approved labeling information recommends the following dose modifications for preexisting liver disease in patients receiving three-hour infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/173\">",
"     173",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total bilirubin &le;1.25 the ULN",
"      <strong>",
"       and",
"      </strong>",
"      AST &lt;10 times ULN &mdash; total dose 175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Total bilirubin 1.26 to 2.0 times ULN",
"      <strong>",
"       and",
"      </strong>",
"      aminotransferases &lt;10 times ULN &mdash; total dose 135",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Total bilirubin 2.01 to 5.0 times ULN",
"      <strong>",
"       and",
"      </strong>",
"      aminotransferases &lt;10 times ULN &mdash; total dose 90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Total bilirubin &gt;5.0 times ULN",
"      <strong>",
"       or",
"      </strong>",
"      aminotransferases &ge;10 times ULN &mdash; not recommended",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the data used to derive these guidelines were from patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    over one hour or with weekly therapy. It is unknown if these dose reduction schema are suitable for such patients, and further studies with a prospective design are needed.",
"   </p>",
"   <p>",
"    For nanoparticle bound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (nab-paclitaxel, Abraxane), the FDA-approved package insert recommends reduced initial doses in patients with breast and non-small cell lung cancer who have moderate hepatic impairment (AST &lt;10 times ULN and bilirubin &ge;1.26 X ULN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    clearance occurs in patients with elevated bilirubin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transaminase levels. In some studies, even a slight or moderate increase in pretreatment bilirubin level was associated with toxic deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/175-177\">",
"     175-177",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for dose reduction in the setting of hepatic dysfunction are variable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The US FDA-approved labeling information suggests that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      not be given if the baseline serum bilirubin is above the ULN, or to patients with AST &gt;1.5 times the ULN in conjunction with an alkaline phosphatase &gt;2.5 times the ULN.",
"      <br/>",
"      <br/>",
"      In the specific setting of gastric cancer when docetaxel is administered in conjunction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      , a 20 percent dose reduction is recommended in patients who develop aminotransferase elevation &gt;2.5 to &le;5 times ULN and alkaline phosphatase &le;2.5 times ULN, or aminotransferases &gt;1.5 to &le;5 times ULN and alkaline phosphatase &gt;2.5 to &le;5 times ULN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/178\">",
"       178",
"      </a>",
"      ]. For more severe hepatic dysfunction, drug discontinuation is recommended.",
"     </li>",
"     <li>",
"      Based upon pharmacokinetic modeling, others have recommended a 20 to 40 percent dose reduction for patients with grade 2 or 3 elevations in aminotransferases (&gt;2.5 to 20 times the ULN, (",
"      <a class=\"graphic graphic_table graphicRef77533 \" href=\"mobipreview.htm?37/40/38540\">",
"       table 1",
"      </a>",
"      )) at baseline in conjunction with elevated levels of alkaline phosphatase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/179\">",
"       179",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    is contraindicated in patients with severe liver dysfunction on the basis of metastatic cancer involvement is unclear. Administration of reduced-dose docetaxel has been successful in at least one report of a patient with breast cancer metastasis-related severe liver dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H714836\">",
"    <span class=\"h4\">",
"     Cabazitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     Cabazitaxel",
"    </a>",
"    is a semisynthetic taxane that is approved for treatment of advanced prostate cancer. There is no published experience with cabazitaxel in patients with impaired hepatic function. However, cabazitaxel is extensively metabolized by the liver, and hepatic impairment is likely to increase exposure to the drug. The FDA-approved labeling guidelines suggest that the drug not be administered to patients with bilirubin levels &ge; the ULN, or if the AST",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ALT are &ge;1.5X ULN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Ixabepilone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is a microtubule inhibitor in the epothilone class that has been approved for treatment of chemotherapy resistant patients with metastatic breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=see_link&amp;anchor=H347515949#H347515949\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Ixabepilone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is metabolized in the liver, and drug exposure is significantly increased in patients with hepatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/181\">",
"     181",
"    </a>",
"    ]. US FDA-approved labeling guidelines for initial dose modification for ixabepilone monotherapy are indicated in the table (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ). Subsequent dosing should be based upon treatment tolerance. Ixabepilone monotherapy is not recommended for aminotransferases &gt;10X ULN, or bilirubin &gt;3X ULN. The combination of ixabepilone with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is contraindicated in patients with aminotransferase elevation &ge;2.5 ULN or serum bilirubin above ULN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H742022\">",
"    <span class=\"h3\">",
"     Eribulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=see_link\">",
"     Eribulin",
"    </a>",
"    mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. Eribulin exposure is increased in patients with mild and moderate hepatic impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/182\">",
"     182",
"    </a>",
"    ]. Dose modification is recommended in the FDA-approved labeling:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Child-Pugh A disease (",
"      <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"       table 5",
"      </a>",
"      ) &ndash; decrease in initial dose to 1.1",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Child-Pugh B disease, decrease initial dose to 0.7",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Child-Pugh C disease, do not administer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Miscellaneous agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    is predominantly metabolized by the liver, and exposure is increased in patients with moderate to severe liver impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/183\">",
"     183",
"    </a>",
"    ]. FDA labeling guidelines suggest a reduced starting dose (0.7",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    in the first cycle for patients with a serum bilirubin &gt;1.5 times ULN, with dose escalation or further dose reduction in subsequent cycles based upon patient tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/184\">",
"     184",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and 5-FU are used in some patients with colorectal cancer prior to the resection of liver metastases. These regimens have been associated with both steatosis and hepatic vascular injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    is mainly eliminated by the liver and to a minor extent by the kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/185,186\">",
"     185,186",
"    </a>",
"    ]. Two main metabolic pathways take place in the liver: conversion into inactive metabolites (via the CYP3A4 isoenzyme) and into the active metabolite SN-38 by carboxylesterase enzymes. Irinotecan clearance is diminished in patients with hepatic dysfunction, and exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function.",
"   </p>",
"   <p>",
"    The tolerability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    in patients with hepatic dysfunction (serum bilirubin &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    has not been established. Specific dosing guidelines for patients with hepatic insufficiency are not available in the US FDA-approved manufacturer's product labeling. However, some clinicians recommend a reduction of the starting dose (eg, from 350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) in patients with a pretreatment serum bilirubin level 1.5 to 3.0 times ULN to minimize the likelihood of diarrhea and neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/93,186,187\">",
"     93,186,187",
"    </a>",
"    ]. Dose reduction may also be needed for patients with a serum bilirubin 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    particularly with weekly administration schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/188,189\">",
"     188,189",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with elevated aminotransferases do not appear to be more sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and dose reduction is probably not needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/187\">",
"     187",
"    </a>",
"    ]. However, the available data are insufficient to make a specific recommendation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Platinum derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    is a rare cause of steatosis and cholestasis at standard doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/190\">",
"     190",
"    </a>",
"    ]. Minor transient elevations in transaminases can occur during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/191\">",
"     191",
"    </a>",
"    ] and are more frequent at higher doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/192\">",
"     192",
"    </a>",
"    ]. Mild reversible increases in alkaline phosphatase and serum aminotransferases have also been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . There is at least one report of carboplatin-induced liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/193\">",
"     193",
"    </a>",
"    ] and one autopsy-documented case of hepatic sinusoidal obstruction syndrome (SOS) in a patient who received high-dose carboplatin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    in addition to multiple other medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/194\">",
"     194",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Hepatic vascular injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and 5-FU are used in some patients with colorectal cancer prior to the resection of liver metastases. These neoadjuvant regimens have been associated with steatosis, hepatic vascular injury, and nodular regenerative hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All three drugs are predominantly renally excreted. No published studies are available to guide dosing in patients with liver dysfunction. Results from single case reports, clinical trials conducted in patients with metastatic colorectal cancer, and from a dose-escalating and pharmacologic study in patients with various tumor types indicate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    can be administered without dose modification, even in patients with severe liver dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/195-197\">",
"     195-197",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H27#H27\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Asparaginase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity is frequent with Escherichia coli-derived L-asparaginase. Hepatotoxicity is characterized by moderate reversible elevation of aminotransferases, bilirubin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alkaline phosphatase. Hyperammonemia may develop as asparagine is broken down.",
"   </p>",
"   <p>",
"    The mechanism is uncertain, but probably involves impaired protein synthesis from asparagine depletion. Liver steatosis, likely due to decreased lipoprotein synthesis, is found at autopsy in 42 to 87 percent of treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/198,199\">",
"     198,199",
"    </a>",
"    ]. Abnormalities of LFTs are less commonly described following administration of PEG-L-asparaginase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/200\">",
"     200",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic clearance of L-asparaginase (L-asp) is not dependent on renal or liver function. As a result, dose modifications are not usually required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Procarbazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity appears to be uncommon with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/201\">",
"     201",
"    </a>",
"    ]. The drug has been implicated as a cause of granulomatous hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/202\">",
"     202",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following oral administration, most",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    is rapidly converted to azo-procarbazine by erythrocyte and hepatic microsomal enzymes. Further metabolism has not been clearly defined. Although dose modification in patients with hepatic dysfunction is probably advisable, no formal guidelines have been published.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    has been rarely reported to produce liver toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/203-205\">",
"     203-205",
"    </a>",
"    ]. One case report describes hydroxyurea-induced hypersensitivity hepatitis with recurrence upon rechallenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/204\">",
"     204",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    is well absorbed from the gastrointestinal tract, and 50 percent of the drug is excreted unchanged in the urine. There are no published guidelines for dose reduction in patients with liver dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627314962\">",
"    <span class=\"h3\">",
"     Arsenic trioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the basis of limited data from patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    for hepatocellular cancer, there appears to be no clear trend toward an increase in systemic exposure to the pharmacologically active metabolites of arsenic trioxide with decreasing levels of hepatic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/206\">",
"     206",
"    </a>",
"    ]. Nevertheless, given the limited amount of available data, caution is advised in the use of the drug in patients with hepatic impairment, and patients with severe hepatic impairment (eg, Child-Pugh C cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    )) should be closely monitored for toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459304121\">",
"    <span class=\"h3\">",
"     Vorinostat",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     Vorinostat",
"    </a>",
"    is an inhibitor of histone deacetylase enzymes; it is used only for treatment of cutaneous T-cell lymphoma. Patients with varying degrees of hepatic dysfunction require dose reduction even though vorinostat pharmacokinetics are unaltered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/207\">",
"     207",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    US FDA labeling recommends reduced doses for patients with mild to moderate hepatic impairment (total bilirubin &gt;1 to 3 X ULN) and that the drug be avoided in those with severe impairment (total bilirubin &gt;3 X ULN). Canadian guidelines recommend avoidance of the drug for all patients with total bilirubin &ge;1.5 X ULN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11221439\">",
"    <span class=\"h2\">",
"     Kinase inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217131934\">",
"    <span class=\"h3\">",
"     Axitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     Axitinib",
"    </a>",
"    is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR)-1, 2, and 3. Clinical trials in advanced renal cell carcinoma have demonstrated up to a 22 percent incidence of elevated aminotransferases with &lt;1 percent being grade 3 or 4. Routine monitoring of liver function studies is recommended during therapy. &nbsp;",
"   </p>",
"   <p>",
"    Patients with Child-Pugh A liver dysfunction require no baseline dose adjustment, while those with Child-Pugh B liver dysfunction require a 50 percent dose reduction. No data are available on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    use in patients with Child-Pugh C liver dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35110980\">",
"    <span class=\"h3\">",
"     Bosutinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    is a multitargeted tyrosine kinase inhibitor that targets Bcr-Abl and the SRC family of tyrosine kinases. Clinical trials in patients with chronic myelogenous leukemia demonstrated transaminase elevation in 14 to 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/208\">",
"     208",
"    </a>",
"    ]. The FDA-approved manufacturer&rsquo;s package insert recommends monthly assay of transaminases for the first three months of treatment and as clinically indicated thereafter. Guidelines for dose reduction in patients with baseline liver impairment and for those who develop severe hepatotoxicity during therapy are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/208\">",
"     208",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217132037\">",
"    <span class=\"h3\">",
"     Crizotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     Crizotinib",
"    </a>",
"    , an orally active inhibitor or the anaplastic lymphoma kinase (ALK), is approved for treatment of advanced or metastatic non-small cell lung cancer if the tumor contains a characteristic EML4-ALK fusion oncogene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link&amp;anchor=H11#H11\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Crizotinib'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    <br/>",
"    In phase II studies, grade 3 or 4 abnormal liver function tests occurred in 4 to 7 percent of treated patients; they were mostly reversible and asymptomatic, and did not recur with lower doses. However, treatment had to be permanently discontinued in 4 of 255 (1.6 percent) of cases.",
"   </p>",
"   <p>",
"    The FDA-approved manufacturer&rsquo;s labeling recommends that treatment be withheld for grade 3 or 4 aminotransferase elevation as long as serum bilirubin is &le;1.5 times the upper limit of normal (ULN); permanent discontinuation is advised for grade 2 or higher aminotransferase elevation if serum bilirubin is &gt;1.5 x ULN.",
"   </p>",
"   <p>",
"    Specific guidelines are not available for dosing in patients with preexisting liver dysfunction, since those with initial serum total bilirubin &gt;1.5 ULN or aminotransferases &gt;2.5 x ULN, were excluded from the clinical trials, even if the abnormalities were considered to be due to metastases. Given the extent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    metabolism in the liver, hepatic impairment is likely to increase plasma crizotinib concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217131947\">",
"    <span class=\"h3\">",
"     Dasatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    is a tyrosine kinase inhibitor that targets Bcr-Abl, KIT, the platelet-derived growth factor receptor (PDGFR), and the SRC family of tyrosine kinases. Baseline liver dysfunction does not require dose modification. Grade 3 and 4 aminotransferase elevations are reported and typically respond to dose reduction or brief treatment interruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217132150\">",
"    <span class=\"h3\">",
"     Erlotinib and gefitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     Erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    are small molecule inhibitors of the TK domain of the epidermal growth factor receptor (EGFR). Both are primarily metabolized in the liver by the cytochrome P450 system.",
"   </p>",
"   <p>",
"    Hepatic dysfunction decreases clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/209\">",
"     209",
"    </a>",
"    ]. Patients with an elevated total serum bilirubin (above the institutional ULN) or Child-Pugh A, B, or C cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    ) should be closely monitored during treatment. Hepatic failure and hepatorenal syndrome, occasionally fatal, have been reported, particularly in patients with preexisting moderate to severe hepatic impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/210,211\">",
"     210,211",
"    </a>",
"    ] and in",
"    <span class=\"nowrap\">",
"     elderly/frail",
"    </span>",
"    patients on multiple medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/212\">",
"     212",
"    </a>",
"    ]. Even if baseline levels are normal, erlotinib should be interrupted or discontinued for total bilirubin &gt;3 times ULN, or for aminotransferase elevation &ge;5 times ULN during treatment.",
"   </p>",
"   <p>",
"    Although the US FDA-approved labeling does not provide specific guidelines, some clinicians recommend a reduced initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    (75 rather than 150 mg) in patients with AST &ge;3 times ULN or serum direct bilirubin 1 to 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/209\">",
"     209",
"    </a>",
"    ]. Others suggest that a reduced starting dose is not needed in those with moderate hepatic impairment (ie, Child-Pugh B cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/213\">",
"     213",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     Gefitinib",
"    </a>",
"    uncommonly causes increased aminotransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/214\">",
"     214",
"    </a>",
"    ]. Compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , there is less information on gefitinib in patients with liver dysfunction. A report of two cirrhotic patients with lung cancer noted no untoward effects using every other day administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/215\">",
"     215",
"    </a>",
"    ]. However, the FDA-approved package insert does not recommend dose reduction even for patients with moderate to severe liver dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/216\">",
"     216",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is a tyrosine kinase inhibitor targeting",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    and KIT that is metabolized by cytochrome P450; as a result, other drugs metabolized through this pathway may increase imatinib concentrations, potentially increasing its hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/217\">",
"     217",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is hepatically metabolized but dosing guidelines for patients with baseline moderate to severe hepatic dysfunction (bilirubin &gt;1.5 times ULN) remain undetermined and are not provided in the",
"    <a class=\"external\" href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b\">",
"     US FDA-approved manufacturer's labeling",
"    </a>",
"    . Some have suggested that the maximal daily recommended dose in patients with mild liver dysfunction (total bilirubin &lt;1.5 times ULN, AST above the ULN) should be no more than 500 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/218\">",
"     218",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    causes elevations in serum LFTs",
"    <span class=\"nowrap\">",
"     (AST/ALT,",
"    </span>",
"    alkaline phosphatase, total bilirubin) in 15 to 20 percent of patients receiving the drug, most commonly during the first 12 months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/219-221\">",
"     219-221",
"    </a>",
"    ]. Hepatotoxicity can be severe, and fatal acute hepatic necrosis has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/220\">",
"     220",
"    </a>",
"    ]. At least one report indicates that treatment with corticosteroids led to resolution of hepatic abnormalities and permitted the resumption of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/221\">",
"     221",
"    </a>",
"    ]. For patients who develop hepatotoxicity during therapy (elevations of total bilirubin &gt;3 x ULN or transaminases &gt;5 x ULN), the",
"    <a class=\"external\" href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b\">",
"     US FDA-approved manufacturer&rsquo;s product information",
"    </a>",
"    recommends withholding treatment until bilirubin &lt;1.5 x ULN and transaminases &lt;2.5 x ULN, then resuming treatment with a reduced dose (eg, if current dose is 400 mg daily, reduce dose to 300 mg daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    is a dual inhibitor of both",
"    <span class=\"nowrap\">",
"     HER2/neu",
"    </span>",
"    (erbB-2) and the EGFR, which is also called erbB-1. Lapatinib has been associated with severe, potentially fatal hepatotoxicity (mainly aminotransferase elevation) in &lt;1 percent of treated patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    is extensively metabolized in the liver. The US FDA-approved labeling guidelines suggest dose reduction for patients with severe hepatic impairment (Child-Pugh class C) who are treated with lapatinib in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ; for lapatinib in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    , they recommend dropping the initial lapatinib dose from 1500 to 1000 mg daily (",
"    <a class=\"graphic graphic_table graphicRef81280 \" href=\"mobipreview.htm?15/14/15597\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/222\">",
"     222",
"    </a>",
"    ]Liver function tests should be monitored at least every four to six weeks during therapy, and the drug discontinued for severe changes in liver function",
"    <span class=\"nowrap\">",
"     (ALT/AST",
"    </span>",
"    &gt;3 times the ULN, bilirubin &gt;2 times the ULN).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217131983\">",
"    <span class=\"h3\">",
"     Nilotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    is a multitargeted tyrosine kinase inhibitor that targets Bcr-Abl, KIT, and PDFGR. Metabolism is primarily hepatic and exposure is increased in patients with impaired hepatic function. The US FDA-approved labeling recommends initial dose reduction in patients with even mild hepatic impairment (defined as Child-Pugh class A cirrhosis) (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    ). The specified dose reductions are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef81280 \" href=\"mobipreview.htm?15/14/15597\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217131874\">",
"    <span class=\"h3\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is an oral agent that targets multiple TKs including VEGFR, PDGFR and KIT. In clinical trials, severe hepatotoxicity (increased aminotransferases and total bilirubin) was seen in approximately 18 percent of patients; two of 977 died with both disease progression and hepatic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/223\">",
"     223",
"    </a>",
"    ]. The FDA-approved package labeling recommends that liver function tests be monitored before initiation of treatment and at weeks 3, 5, 7, 9, 12, and 16, and then as clinically indicated. Treatment should be interrupted or discontinued in the event of hepatotoxicity.",
"   </p>",
"   <p>",
"    Inheritance of certain polymorphisms in the uridine diphosphoglucuronosyltransferase 1A1 (UGT 1A1) enzyme that cause Gilbert's syndrome (the UGT1A1*28 allele) seem to be associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    -induced hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/224\">",
"     224",
"    </a>",
"    ]. These results support the view that some instances of isolated hyperbilirubinemia in these patients represent a benign manifestation of Gilbert's syndrome, and that continuation of pazopanib monotherapy is reasonable in this setting. Genetic testing for the UGT 1A1*28 allele is available (the Invader UGT1A1 Molecular Assay), but most clinicians do not routinely test patients prior to therapy, instead, they follow liver function tests closely as per the FDA recommendations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is metabolized by the liver. Based upon data presented at the 2010 ASCO meeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/225\">",
"     225",
"    </a>",
"    ], US FDA-approved labeling guidelines suggest dose reduction to 200 mg per day for total bilirubin 1.5 to 3 times the ULN, and that the drug not be used in patients with more severe liver impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1157198779\">",
"    <span class=\"h3\">",
"     Ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     Ponatinib",
"    </a>",
"    targets Bcr-Abl, VEGFR, PDGFR, the fibroblast growth factor receptor (FGFR), the SRC family of kinases, KIT, RET, TIE2 and FLT3; it is approved in the United States for treatment of refractory chronic myelogenous leukemia. Ponatinib may result in elevations in ALT, AST, or both, and fatal acute liver failure has been described, sometimes within one week of starting therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/226\">",
"     226",
"    </a>",
"    ]. Liver function tests should be evaluated at baseline, and at least monthly during therapy.",
"   </p>",
"   <p>",
"    Hepatic elimination is the main route of excretion for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    . Patients with moderate to severe (Child-Pugh B or C) hepatic impairment are at increased risk for adverse reactions, and the drug should be avoided in such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15667829\">",
"    <span class=\"h3\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    targets VEGFR1, 2, and 3 in addition to RET, KIT, PDGFR alpha and beta, FGFR1 and 2, and several other membrane-bound and intracellular kinases that are involved in normal cellular function and in pathologic processes. It has been approved in the United States for treatment of metastatic colorectal cancer in patients previously treated with multiple cytotoxic and molecularly targeted therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56909045#H56909045\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Regorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fatal drug-induced liver injury occurred in 0.3 percent of 1100 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    on clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/227\">",
"     227",
"    </a>",
"    ]. In the placebo-controlled CORRECT trial, fatal hepatic failure occurred in 1.6 percent of patients treated with regorafenib for metastatic colorectal cancer (versus 0.4 percent in the placebo group). Biopsy, where available, has shown hepatocyte necrosis with lymphocytic infiltration.",
"   </p>",
"   <p>",
"    The manufacturer recommends baseline liver function tests (ALT, AST, bilirubin) prior to initiating therapy and at least every two weeks during the first two months of treatment. Dose adjustment is not recommended for preexisting mild to moderate hepatic impairment (Child-Pugh A or B cirrhosis), but use of the drug is not recommended in those with Child-Pugh C disease. For hepatotoxicity during treatment, the manufacturer recommends withholding dose until recovery for grade 3 AST or ALT elevations (",
"    <a class=\"graphic graphic_table graphicRef77533 \" href=\"mobipreview.htm?37/40/38540\">",
"     table 1",
"    </a>",
"    ) and to resume therapy at a reduced dose if potential benefit outweighs risk.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    should be discontinued permanently for re-occurrence of",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    &gt;5 x ULN despite dose reduction, or for any",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    &gt;20 X ULN, or for",
"    <span class=\"nowrap\">",
"     AST/ALT&gt;3",
"    </span>",
"    X ULN plus bilirubin &gt;2 X ULN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4072466\">",
"    <span class=\"h3\">",
"     Ruxolitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     Ruxolitinib",
"    </a>",
"    , a kinase inhibitor that selectively inhibits Janus-Associated Kinases (JAKs), is used for treatment of myelofibrosis. It undergoes predominantly hepatic metabolism, and a reduced initial dose is recommended for patients with hepatic impairment and a platelet count of 100,000 to",
"    <span class=\"nowrap\">",
"     150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ;",
"    </span>",
"    use is not recommended for those with hepatic impairment and a platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36922?source=see_link&amp;anchor=H28#H28\">",
"     \"Prognosis and treatment of primary myelofibrosis\", section on 'JAK2 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    is a potent small molecule inhibitor of multiple TKs, including VEGFR. Sorafenib-induced hepatitis is characterized predominantly by a hepatocellular pattern of liver damage with significant increases in transaminases that may result in hepatic failure and death. Uncommonly elevations in the international normalized ratio (INR) or hyperbilirubinemia may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/228,229\">",
"     228,229",
"    </a>",
"    ]. Some have suggested that hyperbilirubinemia correlates with high levels of systemic drug exposure and that both are linked to inheritance of a uridine glucuronosyl 1A1 (UGT1A1)*28 allele, which is associated with reduced enzymatic activity and Gilbert&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/230\">",
"     230",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver function tests should be monitored regularly during treatment. The US FDA-approved labeling for",
"    <a class=\"external\" href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0\">",
"     sorafenib",
"    </a>",
"    recommends that if transaminases are &ldquo;significantly increased&rdquo; without alternative explanation such as viral hepatitis or progressing underlying malignancy that the drug be discontinued.",
"   </p>",
"   <p>",
"    There are conflicting data on the need for dose reduction in patients with preexisting liver dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Results from a phase I study suggest that dose reduction to 200 mg twice a day is required in patients with a bilirubin 1.5 to 3 times the ULN, and that the drug cannot be tolerated with more severe hyperbilirubinemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/228\">",
"       228",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, at least one study in patients treated for advanced hepatocellular cancer concluded that dose reduction is not necessary in patients with mild to moderate aminotransferase elevation (&ge;1.8 times ULN).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    FDA-approved labeling for",
"    <a class=\"external\" href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0\">",
"     sorafenib",
"    </a>",
"    recommends no dose adjustment for Child-Pugh class B impairment, and makes no recommendation for those with Child-Pugh class C cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    ). However, they recommend that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    be discontinued for unexplained significant increases in transaminases during treatment. The tolerance of sorafenib in patients with liver disease is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H19#H19\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Safety in patients with liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204884583\">",
"    <span class=\"h3\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    is another potent small molecule inhibitor of multiple TKs including VEGFR. Hepatotoxicity has been observed in clinical trials, which may result in liver failure (7 of 2281 patients, 0.3 percent); fatalities have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/231\">",
"     231",
"    </a>",
"    ]. Liver function should be monitored prior to and during treatment. The drug should be interrupted for bilirubin levels &gt;3X ULN,",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    &gt;5X ULN and not restarted until resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104381194\">",
"    <span class=\"h3\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    is another orally active inhibitor of several TKs including RET, VEGFR and EGFR. In clinical trials involving patients with medullary thyroid cancer and lung cancer, aminotransferase elevation has been observed in over 20 percent of treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/232,233\">",
"     232,233",
"    </a>",
"    ]. Vandetanib is partially metabolized in the liver. The FDA-approved labeling recommends avoiding use of vandetanib in patients with moderate and severe hepatic impairment (Child-Pugh B or C cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    )), as safety and efficacy have not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952085\">",
"    <span class=\"h3\">",
"     Vemurafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    , an orally available kinase inhibitor of some mutated forms of BRAF, is approved for treatment of metastatic melanoma with a V600E BRAF mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=see_link&amp;anchor=H100472992#H100472992\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'Vemurafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In early clinical trials, grade 3 to 4 abnormalities in liver function tests (GGT, transaminases, bilirubin) occurred in 2 to 12 percent of patients. The FDA-approved manufacturer&rsquo;s labeling recommends monitoring of liver enzymes and bilirubin before initiation and monthly during treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    does not undergo appreciable hepatic metabolism, and adjustment to the starting dose is not needed for patients with preexisting mild to moderate liver impairment. Due to lack of data, the drug should be used with caution in patients with severe liver impairment. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1577577405\">",
"    <span class=\"h2\">",
"     m-TOR inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Metabolism is primarily hepatic, and exposure is increased in patients with mild to moderate hepatic impairment (defined by the US FDA as Child-Pugh class A or B cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    )). A 25 percent dose reduction is recommended for patients with Child-Pugh A cirrhosis being treated for breast cancer, renal cell cancer and pancreatic neuroendocrine tumor, and a 50 percent dose reduction for Child-Pugh B cirrhosis; for those with more severe hepatic impairment in whom the potential benefit outweighs risk, a maximum daily dose of 2.5 mg is recommended. There are different recommendations for patients receiving the drug for subependymal giant cell tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/234\">",
"     234",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204884575\">",
"    <span class=\"h3\">",
"     Temsirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    , another mTOR inhibitor, also undergoes hepatic metabolism. The FDA-approved labeling guidelines recommend a dose reduction to 15 mg weekly in patients with mild hepatic impairment (bilirubin &gt;1 to 1.5 ULN or AST &gt;ULN), and that the drug not be administered to patients with serum bilirubin &gt;1.5X ULN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428907471\">",
"    <span class=\"h2\">",
"     Trastuzumab emtansine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/16/11527?source=see_link\">",
"     Trastuzumab emtansine",
"    </a>",
"    (T-DM1) is an antibody-drug conjugate that incorporates the human epidermal growth factor receptor 2 (HER2)-targeted agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    with the cytotoxic microtubule inhibitor DM1. It is approved for advanced breast cancer in patients previously exposed to trastuzumab and taxanes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=see_link&amp;anchor=H720673240#H720673240\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Ado-trastuzumab emtansine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious hepatotoxicity has been reported, including liver failure and death, in patients treated with T-DM1. The typical pattern is a transient increase in ALT and AST; elevations in serum total bilirubin occur less commonly. Hepatic function should be assessed at baseline and prior to each dose. Dose adjustment is recommended for grade 3 or higher transaminase or bilirubin elevation (",
"    <a class=\"graphic graphic_table graphicRef77533 \" href=\"mobipreview.htm?37/40/38540\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/235\">",
"     235",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical trials of T-DM1, cases of nodular regenerative hyperplasia (NRH) were identified from liver biopsies in three from a total of 884 treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/235\">",
"     235",
"    </a>",
"    ]. NRH is a rare condition that can lead to non-cirrhotic portal hypertension. The overall incidence is unknown. The diagnosis should be considered in patients who develop otherwise unexplained portal hypertension that is confirmed by biopsy. Drug discontinuation is advised. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/14/37095?source=see_link\">",
"     \"Nodular regenerative hyperplasia of the liver\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1577577467\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1577577479\">",
"    <span class=\"h3\">",
"     Interferon alfa-2b",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose interferon is an approved adjuvant treatment for high risk melanoma. High-dose interferon is associated with significant toxicity, including significant aminotransferase elevation, requiring dose adjustment and possibly treatment discontinuation. Aminotransferase elevation &gt;5 times normal requires dose interruption until resolution to grade 1. Treatment should then be resumed at a 33 percent reduced dose. A second event is managed in the same manner; a third event requires permanent discontinuation of interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/236\">",
"     236",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89656322\">",
"    <span class=\"h3\">",
"     Pegylated interferon alfa (IFN-alfa)",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFN-alfa is used as adjuvant chemotherapy for surgically resected high-risk melanoma and has been used for over a decade in treatment of hepatitis C. A randomized trial comparing observation to pegylated IFN-alfa-2b for adjuvant therapy of resected melanoma revealed grade 3 or 4 hepatotoxicity in 11 percent of IFN-alfa-2b treated patients compared with &lt;2 percent of the observation group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/237\">",
"     237",
"    </a>",
"    ]. A trial examining high-dose IFN-alfa-2b (15 X 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     U/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for 5 of 7 days per week) for one month followed by randomization to observation versus continuation of IFN-alfa-2b at a reduced dose for one year revealed grade 1 and 2 hepatoxicity in 41 to 75 percent of patients, and grade 3 and 4 hepatotoxicity in 6 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/238\">",
"     238",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatotoxicity will generally subside with cessation of treatment, though experience with IFN-induced hepatotoxicity occurring during hepatitis C treatment indicates that this may be in the form of autoimmune liver injury requiring immunosuppression to reverse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/239\">",
"     239",
"    </a>",
"    ]. The US FDA-approved manufacturer&rsquo;s labeling suggests treatment be discontinued for hepatic decompensation or severe hepatic injury (Child-Pugh class B or C) during treatment. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1577577448\">",
"    <span class=\"h3\">",
"     Ipilimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    is a monoclonal antibody directed against CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on the T cell surface. As a treatment for advanced melanoma, the presumed mechanism of action of ipilimumab is to break down tolerance to the tumor-associated antigens in the melanoma. At the same time, this may result in decreased tolerance to self antigens. A wide range of immune-mediated adverse events have been observed in patients treated with ipilimumab, including severe and potentially fatal inflammation of the liver, which is most commonly manifested as elevation of aminotransferases and hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link&amp;anchor=H262060483#H262060483\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Hepatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     COMBINATION CHEMOTHERAPY REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of tumors are treated with combination rather than single agent therapy; typically, the individual agents have different mechanisms of action and toxicity profiles. The potential for greater tumor cell kill is sometimes accompanied by greater toxicity, including hepatotoxicity. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant therapy for breast cancer &mdash; Transient abnormalities in liver function tests are commonly observed in women receiving adjuvant chemotherapy for early stage breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Approximately one-half to three-fourths of women receiving adjuvant CAF (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and 5-FU) develop mild elevations in aminotransferases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/240,241\">",
"       240,241",
"      </a>",
"      ]. These usually appear within the first three months of therapy and they may persist, normalizing within one year of treatment cessation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/241\">",
"       241",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (CMF) has been associated with abnormal liver function tests and focal defects on radionuclide liver scans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/242,243\">",
"       242,243",
"      </a>",
"      ]; in one series, liver biopsy specimens showed severe local inflammation. Although rarely necessary, liver biopsy may be required in this setting to exclude tumor metastases and confirm the impression of drug-induced changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"       Carmustine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      &mdash; Severe and unexpected hepatotoxicity has been reported in patients treated with carmustine plus etoposide for either a brain tumor or relapsed Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/244,245\">",
"       244,245",
"      </a>",
"      ]. In one series, two of four patients receiving high doses of carmustine and etoposide for high-grade glioma developed fatal ascites, hyperbilirubinemia, and thrombocytopenia; a third had transient ascites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/244\">",
"       244",
"      </a>",
"      ]. This combination should be used only cautiously, if at all.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      and 6-MP &mdash; The combination of doxorubicin and 6-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      (6-MP) in patients with refractory leukemia has produced unexpected hepatotoxicity. In a series of 11 cases, hyperbilirubinemia and elevations in AST and alkaline phosphatase followed each treatment course, although levels returned to baseline between treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/2/44074/abstract/246\">",
"       246",
"      </a>",
"      ]. At autopsy, intrahepatic cholestasis, hepatocellular necrosis, leukemic infiltration, and fatty change were noted in the liver. It was postulated that intracellular accumulation of doxorubicin might have potentiated the hepatotoxic effects of 6-MP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10042421\">",
"    <span class=\"h1\">",
"     LIVERTOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information on chemotherapy-induced liver injury is available from the",
"    <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"     LiverTox",
"    </a>",
"    , a collaborative effort of the Liver Disease Research Branch of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) and the National Library of Medicine (NLM).",
"    <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"     LiverTox",
"    </a>",
"    is a freely accessible website that provides continuously updated comprehensive and evidence-based information about the clinical features of liver injury from drugs, dietary supplements, and herbal products along with a complete and annotated list of references.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/6/23651?source=see_link\">",
"       \"Patient information: Toxic hepatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy agents, either alone or in combination with other drugs and radiation, may cause indirect or direct hepatotoxicity. Furthermore, abnormal liver function may alter drug metabolism and increase the risk of extrahepatic toxicity.",
"   </p>",
"   <p>",
"    Guidelines on dose modification for patients with preexisting hepatic disease are largely empiric. For some agents, including the vinca alkaloids, taxanes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    , anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    , there is agreement on the need for dose adjustment (or avoidance altogether) in patients with preexisting liver dysfunction in order to avoid excessive systemic toxicity (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81280 \" href=\"mobipreview.htm?15/14/15597\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is less agreement on the need for dose reduction for other agents whose clearance is dependent upon liver metabolism, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , 6-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Infection with hepatitis B (HBV) or hepatitis C (HCV) is a common disorder that can be exacerbated with cytotoxic chemotherapy. A growing number of studies have demonstrated that prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    can reduce both the incidence of reactivation and its severity in patients who are HBsAg positive. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hepatitis B'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/1\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/2\">",
"      Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005; 41:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/3\">",
"      Chamilos G, Luna M, Lewis RE, et al. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther 2007; 29:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/4\">",
"      Umrethia M, Ghosh PK, Majithya R, Murthy RS. 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity. Cancer Invest 2007; 25:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/5\">",
"      Erichsen C, J&ouml;nsson PE. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 1984; 27:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/6\">",
"      Greenstone MA, Dowd PM, Mikhailidis DP, Scheuer PJ. Hepatic vascular lesions associated with dacarbazine treatment. Br Med J (Clin Res Ed) 1981; 282:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/7\">",
"      Asbury RF, Rosenthal SN, Descalzi ME, et al. Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/8\">",
"      Ceci G, Bella M, Melissari M, et al. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 1988; 61:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/9\">",
"      Sutherland CM, Krementz ET. Hepatic toxicity of DTIC. Cancer Treat Rep 1981; 65:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/10\">",
"      F&eacute;aux de Lacroix W, Runne U, Hauk H, et al. Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment. Cancer Treat Rep 1983; 67:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/11\">",
"      Raine J, Bowman A, Wallendszus K, Pritchard J. Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group. J Clin Oncol 1991; 9:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/12\">",
"      Joensuu H, S&ouml;derstr&ouml;m KO, Nikkanen V. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer 1986; 58:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/13\">",
"      Houghton AN, Shafi N, Rickles FR. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report. Cancer 1979; 44:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/14\">",
"      Gill RA, Onstad GR, Cardamone JM, et al. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 1982; 96:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/15\">",
"      Stoneham S, Lennard L, Coen P, et al. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 123:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/16\">",
"      Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986; 104:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/17\">",
"      Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/18\">",
"      Khozouz RF, Huq SZ, Perry MC. Radiation-induced liver disease. J Clin Oncol 2008; 26:4844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/19\">",
"      Hansen MM, Ranek L, Walbom S, Nissen NI. Fatal hepatitis following irradiation and vincristine. Acta Med Scand 1982; 212:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/20\">",
"      Kun LE, Camitta BM. Hepatopathy following irradiation and adriamycin. Cancer 1978; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/21\">",
"      Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/22\">",
"      B&eacute;nichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/23\">",
"      Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/24\">",
"      Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/25\">",
"      Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/26\">",
"      Yeo W, Mo FK, Chan SL, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007; 45:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/27\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/28\">",
"      Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/29\">",
"      de Pree C, Giostra E, Galetto A, et al. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann Oncol 1994; 5:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/30\">",
"      Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 2004; 16:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/31\">",
"      Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/32\">",
"      Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/33\">",
"      Faggioli P, De Paschale M, Tocci A, et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997; 82:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/34\">",
"      Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/35\">",
"      Khan S, Ramwani JJ, O'Brien PJ. Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation. Biochem Pharmacol 1992; 43:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/36\">",
"      Aubrey DA. Massive hepatic necrosis after cyclophosphamide. Br Med J 1970; 3:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/37\">",
"      Walters D, Robinson RG, Dick-Smith JB, et al. Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide. Med J Aust 1972; 2:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/38\">",
"      Bacon AM, Rosenberg SA. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982; 97:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/39\">",
"      Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/40\">",
"      Snyder LS, Heigh RI, Anderson ML. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin Proc 1993; 68:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/41\">",
"      Shaunak S, Munro JM, Weinbren K, et al. Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. Q J Med 1988; 67:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/42\">",
"      Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1984; 26:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/43\">",
"      Matthias M, Saul G. [Clinical aspects of the excretion of alkylating cyclophosphamide metabolites in the urine of tumor bearing patients]. Onkologie 1978; 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/44\">",
"      Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/45\">",
"      Paschke R, Worst P, Brust J, Queisser W. [Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie 1988; 11:273.",
"     </a>",
"    </li>",
"    <li>",
"     IFEX (sterile ifosfamide) package insert, Bristol-Myers Squibb.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/47\">",
"      Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/48\">",
"      Desmet VJ. Drug-induced liver disease: pathogenetic mechanisms and histopathological lesions. Eur J Med 1993; 2:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/49\">",
"      Lazarus HM, Herzig RH, Graham-Pole J, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/50\">",
"      Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/51\">",
"      AMROMIN GD, DELIMAN RM, SHANBROM E. Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 1962; 42:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/52\">",
"      KOLER RD, FORSGREN AL. Hepatotoxicity due to chlorambucil; report of a case. J Am Med Assoc 1958; 167:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/53\">",
"      Morris LE, Guthrie TH Jr. Busulfan-induced hepatitis. Am J Gastroenterol 1988; 83:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/54\">",
"      Underwood JC, Shahani RT, Blackburn EK. Jaundice after treatment of leukemia with busulphan. Br Med J 1971; 1:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/55\">",
"      Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/56\">",
"      Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 2012; 23:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/57\">",
"      Goldbecker A, Tryc AB, Raab P, et al. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol 2011; 103:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/58\">",
"      Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced liver injury. Acta Neurol Belg 2011; 111:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/59\">",
"      Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 1983; 32:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/60\">",
"      De Vita VT, Carbone PP, Owens AH Jr, et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 1965; 25:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/61\">",
"      Phillips GL, Fay JW, Herzig GP, et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 1983; 52:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/62\">",
"      Hoogstraten B, Gottlieb JA, Caoili E, et al. CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study. Cancer 1973; 32:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/63\">",
"      Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/64\">",
"      Schein PS, O'Connell MJ, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 1974; 34:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/65\">",
"      Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/66\">",
"      Pizzuto J, Avil&eacute;s A, Ramos E, et al. Cytosine arabinoside induced liver damage: histopathologic demonstration. Med Pediatr Oncol 1983; 11:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/67\">",
"      George CB, Mansour RP, Redmond J 3rd, Gandara DR. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 1984; 54:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/68\">",
"      Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986; 70:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/69\">",
"      Kremer WB. Drugs five years later: cytarabine. Ann Intern Med 1975; 82:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/70\">",
"      Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986; 81:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/71\">",
"      Koren G, Beatty K, Seto A, et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992; 26:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/72\">",
"      Bateman JR, Pugh RP, Cassidy FR, et al. 5-fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971; 28:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/73\">",
"      Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/74\">",
"      Nikolic-Tomasevic Z, Jelic S, Cassidy J, et al. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. Cancer Chemother Pharmacol 2005; 56:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/75\">",
"      Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/76\">",
"      Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/77\">",
"      Hohn D, Melnick J, Stagg R, et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/78\">",
"      Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/79\">",
"      Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/80\">",
"      Doria MI Jr, Shepard KV, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 1986; 58:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/81\">",
"      Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/82\">",
"      Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/83\">",
"      Ito K, Ito H, Kemeny NE, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol 2012; 19:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/84\">",
"      Kemeny MM, Battifora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/85\">",
"      Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/86\">",
"      Pettavel J, Gardiol D, Bergier N, Schnyder P. Fatal liver cirrhosis associated with long-term arterial infusion of floxuridine. Lancet 1986; 2:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/87\">",
"      Shepard KV, Levin B, Karl RC, et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985; 3:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/88\">",
"      Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999; 26:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/89\">",
"      Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anticancer Drugs 1998; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/90\">",
"      Robinson K, Lambiase L, Li J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003; 48:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/91\">",
"      Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/92\">",
"      Teusink AC, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 2010; 44:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/93\">",
"      Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist 2007; 12:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/94\">",
"      EINHORN M, DAVIDSOHN I. HEPATOTOXICITY OF MERCAPTOPURINE. JAMA 1964; 188:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/95\">",
"      Shorey J, Schenker S, Suki WN, Combes B. Hepatotoxicity of mercaptopurine. Arch Intern Med 1968; 122:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/96\">",
"      Berkovitch M, Matsui D, Zipursky A, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. Med Pediatr Oncol 1996; 26:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/97\">",
"      McILVANIE SK, MACCARTHY JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 1959; 14:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/98\">",
"      CLARK PA, HSIA YE, HUNTSMAN RG. Toxic complications of treatment with 6-mercaptopurine; two cases with hepatic necrosis and intestinal ulceration. Br Med J 1960; 1:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/99\">",
"      Adamson PC, Zimm S, Ragab AH, et al. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990; 26:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/100\">",
"      Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/101\">",
"      Rosman M, Bertino JR. Azathioprine. Ann Intern Med 1973; 79:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/102\">",
"      Romagnuolo J, Sadowski DC, Lalor E, et al. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/103\">",
"      Small P, Lichter M. Probable azathioprine hepatotoxicity: a case report. Ann Allergy 1989; 62:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/104\">",
"      Barrowman JA, Kutty PK, Ra MU, Huang SN. Sclerosing hepatitis and azathioprine. Dig Dis Sci 1986; 31:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/105\">",
"      M&eacute;nard DB, Gisselbrecht C, Marty M, et al. Antineoplastic agents and the liver. Gastroenterology 1980; 78:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/106\">",
"      Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. Ann Intern Med 1976; 85:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/107\">",
"      Satti MB, Weinbren K, Gordon-Smith EC. 6-thioguanine as a cause of toxic veno-occlusive disease of the liver. J Clin Pathol 1982; 35:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/108\">",
"      Krivoy N, Raz R, Carter A, Alroy G. Reversible hepatic veno-occlusive disease and 6-thioguanine. Ann Intern Med 1982; 96:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/109\">",
"      Larrey D, Fr&eacute;neaux E, Berson A, et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988; 29:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/110\">",
"      Council on Drugs. Evaluation of two antineoplastic agents: pipobroman (Vercyte) and thioguanine. JAMA 1967; 200:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/111\">",
"      Ruymann FB, Mosijczuk AD, Sayers RJ. Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA 1977; 238:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/112\">",
"      Fried M, Kalra J, Ilardi CF, Sawitsky A. Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia. Cancer 1987; 60:2548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/113\">",
"      Kumari TP, Shanvas A, Mathews A, Kusumakumary P. Hepatocellular carcinoma: a rare late event in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/114\">",
"      Leme PR, Creaven PJ, Allen LM, Berman M. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep 1975; 59:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/115\">",
"      Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978; 23:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/116\">",
"      Avil&eacute;s A, Herrera J, Ramos E, et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/117\">",
"      Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974; 33:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/118\">",
"      Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993; 53:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/119\">",
"      Johnson PJ, Dobbs N, Kalayci C, et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992; 65:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/120\">",
"      Chan KK, Chlebowski RT, Tong M, et al. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 1980; 40:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/121\">",
"      Doroshow J, Chan K. Relationship between doxorubicin clearance and indocyanine green dye pharmacokinetics in patients with hepatic dysfunction (abstract). Proc Am Soc Clin Oncol 1982; 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/122\">",
"      Benjamin RS. A practical approach to adriamycin (NSC 123127) toxicology. Cancer Chemother Rep 1975; 6:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/123\">",
"      Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998; 34:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/124\">",
"      Yarbro JW, Kennedy BJ. A comparison of the rate of recovery from inhibition of RNA synthesis in mouse liver and transplantable glioma. Cancer Res 1967; 27:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/125\">",
"      Gurevich I, Akerley W. Treatment of the jaundiced patient with breast carcinoma: case report and alternate therapeutic strategies. Cancer 2001; 91:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/126\">",
"      Dobbs NA, Twelves CJ, Gregory W, et al. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer 2003; 39:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/127\">",
"      Paciucci PA, Sklarin NT. Mitoxantrone and hepatic toxicity. Ann Intern Med 1986; 105:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/128\">",
"      Vredenburgh JJ, McIntyre OR, Cornwell GG 3rd, et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Med Pediatr Oncol 1988; 16:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/129\">",
"      Chlebowski RT, Bulcavage L, Henderson IC, et al. Mitoxantrone use in breast cancer patients with elevated bilirubin. Breast Cancer Res Treat 1989; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/130\">",
"      Bedikian AY, Stroehlein J, Korinek J, et al. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer. Am J Clin Oncol 1983; 6:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/131\">",
"      Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997; 10:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/132\">",
"      Blum RH, Carter SK, Agre K. A clinical review of bleomycin--a new antineoplastic agent. Cancer 1973; 31:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/133\">",
"      Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972; 77:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/134\">",
"      Robert J, Barbier P, Manaster J, Jacobs E. Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice. Digestion 1968; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/135\">",
"      Lazarus HM, Gottfried MR, Herzig RH, et al. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 1982; 49:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/136\">",
"      Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976; 3:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/137\">",
"      van Hazel GA, Scott M, Rubin J, et al. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep 1983; 67:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/138\">",
"      Buroker TR, Kim PN, Baker LH, et al. Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. Med Pediatr Oncol 1978; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/139\">",
"      Konits PH, Aisner J, van Echo DA, et al. Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 1981; 48:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/140\">",
"      Bukowski RM, Schacter LP, Groppe CW, et al. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 1982; 50:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/141\">",
"      Tefft M, Traggis D, Filler RM. Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia. Am J Roentgenol Radium Ther Nucl Med 1969; 106:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/142\">",
"      Ludwig R, Weirich A, Abel U, et al. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999; 33:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/143\">",
"      Pritchard J, Raine J, Wallendszus K. Hepatotoxicity of actinomycin-D. Lancet 1989; 1:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/144\">",
"      McClay E, Lusch CJ, Mastrangelo MJ. Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep 1987; 71:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/145\">",
"      el Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. Cancer 1984; 54:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/146\">",
"      Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/147\">",
"      Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982; 8:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/148\">",
"      Van den Berg HW, Desai ZR, Wilson R, et al. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982; 8:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/149\">",
"      Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/150\">",
"      Kitzen JJ, Puozzo C, de Jonge MJ, et al. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. Eur J Cancer 2010; 46:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/151\">",
"      Issell BF, Crooke ST. Etoposide (VP-16-213). Cancer Treat Rev 1979; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/152\">",
"      Tran A, Housset C, Boboc B, et al. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991; 12:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/153\">",
"      Johnson DH, Greco FA, Wolff SN. Etoposide-induced hepatic injury: a potential complication of high-dose therapy. Cancer Treat Rep 1983; 67:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/154\">",
"      Chan HY, Meyers FJ, Lewis JP. High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 1987; 20:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/155\">",
"      Perry MC, Moertel CG, Schutt AJ, et al. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. Cancer Treat Rep 1976; 60:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/156\">",
"      D'Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986; 46:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/157\">",
"      Arbuck SG, Douglass HO, Crom WR, et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986; 4:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/158\">",
"      Hande KR, Wolff SN, Greco FA, et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990; 8:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/159\">",
"      Aita P, Robieux I, Sorio R, et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 43:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/160\">",
"      Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/161\">",
"      Stewart CF. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994; 34 Suppl:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/162\">",
"      Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/163\">",
"      Liu B, Earl HM, Poole CJ, et al. Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 1995; 36:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/164\">",
"      Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/165\">",
"      Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/166\">",
"      Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/167\">",
"      Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001; 27:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/168\">",
"      Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995; 6:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/169\">",
"      Panday VR, Huizing MT, Willemse PH, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997; 24:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/170\">",
"      Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/171\">",
"      Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/172\">",
"      Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14:1877.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23101 (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4 (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/175\">",
"      Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/176\">",
"      Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 1996; 7 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/177\">",
"      Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23492 (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/179\">",
"      Minami H, Kawada K, Sasaki Y, et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 2009; 100:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/180\">",
"      Samur M. Docetaxel and liver dysfunction: is it absolutely contraindicated? Am J Clin Oncol 2001; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=31271&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30d60d6d4e23472141 (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     Witteveen, P, Marchetti, S, Mergui-Roelvink, M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment (Abstract # 2582). J Clin Oncol 2010; 28:224s. Abstraact available online at file://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=48260 (Accessed on February 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/183\">",
"      LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res 2012; 18:2954.",
"     </a>",
"    </li>",
"    <li>",
"     Bortezomib (Velcade). FDA-approved manufacturer's package insert. US National Library of Medicine www.dailymed.nlm.nih.gov (Accessed on April 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/185\">",
"      Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/186\">",
"      Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/187\">",
"      Venook AP, Enders Klein C, Fleming G, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/188\">",
"      Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/189\">",
"      Kramar A, Gourgou-Bourgade S, Ychou M. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan. J Clin Oncol 2005; 23:650; author reply 650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/190\">",
"      Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treat Rep 1978; 62:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/191\">",
"      Hill JM, Loeb E, MacLellan A, et al. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 1975; 59:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/192\">",
"      Pollera CF, Ameglio F, Nardi M, et al. Cisplatin-induced hepatic toxicity. J Clin Oncol 1987; 5:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/193\">",
"      Hruban RH, Sternberg SS, Meyers P, et al. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 1991; 9:263.",
"     </a>",
"    </li>",
"    <li>",
"     Christian MC. Two toxicities associated with carboplatin use: a. gross hematuria b. hepatic veno-occlusive disease. Department of Health &amp; Human Services bulletin, National Institutes of Health; National Cancer Institute, Bethesda, MD 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/195\">",
"      Fakih MG. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology 2004; 67:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/196\">",
"      Synold TW, Takimoto CH, Doroshow JH, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007; 13:3660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/197\">",
"      Grenader T, Goldberg A, Gabizon A. Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel. Anticancer Drugs 2009; 20:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/198\">",
"      Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969; 281:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/199\">",
"      Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/200\">",
"      Muss HB, Spell N, Scudiery D, et al. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs 1990; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/201\">",
"      Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ. Procarbazine-induced hepatotoxicity: case report and review of the literature. Pharmacotherapy 2010; 30:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/202\">",
"      McMaster KR 3rd, Hennigar GR. Drug-induced granulomatous hepatitis. Lab Invest 1981; 44:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/203\">",
"      THURMAN WG, BLOEDOW C, HOWE CD, et al. A phase I study of hydroxyurea. Cancer Chemother Rep 1963; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/204\">",
"      Heddle R, Calvert AF. Hydroxyurea induced hepatitis. Med J Aust 1980; 1:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/205\">",
"      McDonald GB, Tirumali N. Intestinal and liver toxicity of antineoplastic drugs. West J Med 1984; 140:250.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing information for Arsenic trioxide available online at  file://www.trisenox.com/pdf/TRISENOX_pi.pdf (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/207\">",
"      Ramalingam SS, Kummar S, Sarantopoulos J, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2010; 28:4507.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf?et_cid=29953027&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203341lbl.pdf (Accessed on September 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/209\">",
"      Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007; 25:3055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/210\">",
"      Liu W, Makrauer FL, Qamar AA, et al. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007; 5:917.",
"     </a>",
"    </li>",
"    <li>",
"     Alert letter available online at www.fda.gov/medwatch/safety/2008/tarceva_dhcp.letter.pdf (Accessed on April 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/212\">",
"      Pellegrinotti M, Fimognari FL, Franco A, et al. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother 2009; 43:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/213\">",
"      O'Bryant CL, Haluska P, Rosen L, et al. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol 2012; 69:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/214\">",
"      Ho C, Davis J, Anderson F, et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 2005; 23:8531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/215\">",
"      Kim YH, Mio T, Mishima M. Gefitinib for non-small cell lung cancer patients with liver cirrhosis. Intern Med 2009; 48:1677.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18708&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30d60d6d4e23472141 (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/217\">",
"      Kikuchi S, Muroi K, Takahashi S, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 2004; 45:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/218\">",
"      Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/219\">",
"      O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/220\">",
"      Cross TJ, Bagot C, Portmann B, et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006; 81:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/221\">",
"      Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006; 91:ECR27.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808.",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17796&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30d60d6d4e23472141 (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/224\">",
"      Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010; 102:1371.",
"     </a>",
"    </li>",
"    <li>",
"     Shibata S, Longmate J, Chung VM, et al. A phase I and pharmacokinetic single agent study of pazopanib in patients with advanced malignancies and varying degrees of liver dysfunction (Abstract 2571). J Clin Oncol 2010; 28:221s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=44621 (Accessed on January 06, 2012).",
"    </li>",
"    <li>",
"     US FDA-approved manufacturer's package insert available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71 (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's product information, available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7 (Accessed on October 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/228\">",
"      Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/229\">",
"      Meza-Junco J, Chu QS, Christensen O, et al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/230\">",
"      Peer CJ, Sissung TM, Kim A, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 2012; 18:2099.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=19678#nlm34068-7 (Accessed on August 05, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/232\">",
"      Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA drug approval summary for vandetanib in medullary thyroid cancer available online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's labeling for everolimus available online at file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=43629 (Accessed on June 17, 2011).",
"    </li>",
"    <li>",
"     FDA-approved prescribing information for trastuzumab emtansine available at file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf?et_cid=31141095&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125427lbl.pdf (Accessed on February 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/236\">",
"      Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/237\">",
"      Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/238\">",
"      Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009; 27:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/239\">",
"      Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/240\">",
"      Fetting JH, Gray R, Fairclough DL, et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol 1998; 16:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/241\">",
"      Larroquette CA, Hortobagyi GN, Buzdar AU, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. JAMA 1986; 256:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/242\">",
"      Vaughan WP, Wilcox PM, Alderson PO, et al. Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breast. Med Pediatr Oncol 1979; 7:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/243\">",
"      Hirvikoski PP, Kumpulainen EJ, Johansson RT. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. Breast Cancer Res Treat 1997; 44:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/244\">",
"      Wolff SN. High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity. Cancer Treat Rep 1986; 70:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/245\">",
"      Fleming DR, Wolff SN, Fay JW, et al. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. Leuk Lymphoma 1999; 35:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/2/44074/abstract/246\">",
"      Minow RA, Stern MH, Casey JH, et al. Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and Adriamycin. Cancer 1976; 38:1524.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2837 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44074=[""].join("\n");
var outline_f43_2_44074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H56\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ASPECTS OF DRUG-INDUCED HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2739719\">",
"      - Liposomal drug formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Hepatic vascular injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Irradiation plus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Impact of preexisting liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CYTOTOXIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nitrosoureas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antimetabolites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cytarabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Fluorouracil and capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Floxuridine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Mercaptopurine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Thioguanine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10245190\">",
"      - Pemetrexed and pralatrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Antitumor antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Mitoxantrone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Bleomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Mitomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Dactinomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Dacarbazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Tubulin-acting agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Vinca alkaloids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Etoposide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H714826\">",
"      Paclitaxel and docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H714836\">",
"      Cabazitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Ixabepilone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H742022\">",
"      - Eribulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Miscellaneous agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Irinotecan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Platinum derivatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Asparaginase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Procarbazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H627314962\">",
"      - Arsenic trioxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H459304121\">",
"      - Vorinostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      MOLECULARLY TARGETED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11221439\">",
"      Kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H217131934\">",
"      - Axitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35110980\">",
"      - Bosutinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H217132037\">",
"      - Crizotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H217131947\">",
"      - Dasatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H217132150\">",
"      - Erlotinib and gefitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H217131983\">",
"      - Nilotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H217131874\">",
"      - Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1157198779\">",
"      - Ponatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15667829\">",
"      - Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4072466\">",
"      - Ruxolitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H204884583\">",
"      - Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104381194\">",
"      - Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H952085\">",
"      - Vemurafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1577577405\">",
"      m-TOR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Everolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H204884575\">",
"      - Temsirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H428907471\">",
"      Trastuzumab emtansine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1577577467\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1577577479\">",
"      - Interferon alfa-2b",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89656322\">",
"      - Pegylated interferon alfa (IFN-alfa)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1577577448\">",
"      - Ipilimumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      COMBINATION CHEMOTHERAPY REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10042421\">",
"      LIVERTOX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/40/38540\" title=\"table 1\">",
"      NCI CTCAE hepatic toxicity grading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/11/21694\" title=\"table 2\">",
"      Chemo dose modify liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/6/9325\" title=\"table 3\">",
"      FUdR dose modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 4\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 5\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/14/15597\" title=\"table 6\">",
"      Chemo dose mod molc agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/63/21494?source=related_link\">",
"      Liver biochemical tests that detect injury to hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/14/37095?source=related_link\">",
"      Nodular regenerative hyperplasia of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=related_link\">",
"      Nonsurgical local treatment strategies for colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36922?source=related_link\">",
"      Prognosis and treatment of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7081?source=related_link\">",
"      Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_2_44075="Romhilt Estes point score";
var content_f43_2_44075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Romhilt-Estes point score system for ECG diagnosis of LVH",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criterion",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Any limb R ware or S wave &ge;2.0 mV (20 mm)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         OR",
"        </strong>",
"        S in V1 or S in V2 &ge; 3.0 mV (30 mm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         OR",
"        </strong>",
"        &nbsp;R in V5 or R in V6 &ge;3.0 mV (30 mm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        ST-T wave changes typical of LVH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Taking digitalis",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Not taking digitalis",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Left atrial abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        P terminal force in V1 is 1 mm or more in depth with a duration&nbsp;40 ms (0.04 sec)",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left axis deviation &ge;-30&ordm;",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        QRS duration &ge;90 ms",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrinsicoid deflection in V5 or V6 &ge;50 ms (0.05 sec)*",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A score of 5 or more indicates \"definite\" LVH; a score of 4 indicates \"probable\" LVH.",
"     <br>",
"      * Intrinsicoid deflection is defined as interval between beginning of QRS interval and the peak of the R wave.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44075=[""].join("\n");
var outline_f43_2_44075=null;
var title_f43_2_44076="Clinical features bvFTD";
var content_f43_2_44076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The clinical diagnostic features of behavioral variant FTD: Clinical profile",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Character change and disordered social conduct are the dominant features initially and throughout the disease course. Instrumental functions of perception, spatial skills, praxis, and memory are intact or relatively well preserved.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        I. Core diagnostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Insidious onset and gradual progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Early decline in social interpersonal conduct",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. Early impairment in regulation of personal conduct",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Early emotional blunting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E. Early loss of insight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        II. Supportive diagnostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Behavioral disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Decline in personal hygiene and grooming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Mental rigidity and inflexibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Distractibility and impersistence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4. Hyperorality and dietary changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5. Perseverative and stereotyped behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        6. Utilization behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Speech and language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Altered speech output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        a. Aspontaneity and economy of speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        b. Press of speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Stereotypy of speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Echolalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4. Perseveration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5. Mutism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. Physical signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Primitive reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Akinesia, rigidity, and tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4. Low and labile blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Investigations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Neuropsychology: significant impairment on frontal lobe tests in the absence of severe amnesia, aphasia, or perceptuospatial disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Electroencephalography: normal on conventional EEG despite clinically evident dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Brain imaging (structural and/or functional): predominant frontal and/or anterior temporal abnormality",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51:1546. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44076=[""].join("\n");
var outline_f43_2_44076=null;
var title_f43_2_44077="Echo for chest pain in ER";
var content_f43_2_44077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Echocardiography to evaluate chest pain in emergency room",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow chart showing breakdown of two-dimensional echocardiographic findings in relation to the occurrence of acute myocardial infarction in 180 patients presenting to the emergency room with chest pain.",
"    <div class=\"footnotes\">",
"     2DE: two-dimensional echocardiography; RWMA: regional wall motion abnormality; AMI: acute myocardial infarction; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sabia P, Afrookteh A, Touchstone DA, et al. Circulation 1991; 84 (Suppl I):I-85.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44077=[""].join("\n");
var outline_f43_2_44077=null;
var title_f43_2_44078="Etonogestrel implant";
var content_f43_2_44078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Etonogestrel implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Implanon&reg; is 40 mm in length and 2 mm in diameter. It is composed of a solid core of Evatane&reg; with the crystals of etonogestrel imbedded within the core. Surrounding the core is a thin layer of evatane (0.06 mm thick) that controls the rate which etonogestrel is released. The rigidity of the implant pertains to its ease of removal and resistance to fracture during removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Organon USA, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44078=[""].join("\n");
var outline_f43_2_44078=null;
var title_f43_2_44079="Mechanism nictonic acid action";
var content_f43_2_44079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Mechanisms of action of nicotinic acid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nicotinic acid inhibits the mobilization of free fatty acids (FFA) from peripheral adipose tissue to the liver. As a consequence of this decrease or an additional hepatic effect, the synthesis and secretion of very low density lipoprotein (VLDL) are reduced, and the conversion of VLDL to low density lipoprotein (LDL) is decreased. Nicotinic acid can also increase serum high-density lipoprotein (HDL) cholesterol concentrations by up to 30 percent; the mechanism responsible for this effect is a reduction in lipid transfer of cholesterol from HDL to VLDL and delayed HDL clearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Knopp, RH, Ginsberg, J, Albers, JJ, et al. Metabolism 1985; 34:642. Copyright &copy; W.B. Saunders Company. This material may not be reproduced, stored in a retrieval system, or transmitted in any form or by any means without the prior written permission of the publisher.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_2_44079=[""].join("\n");
var outline_f43_2_44079=null;
